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Vasculopathy is a pathological process occurring in the blood vessel wall, which 
could affect the haemostasis and physiological functions of all the vital 
tissues/organs and is one of the main underlying causes for a variety of human 
diseases including cardiovascular diseases. Current pharmacological 
interventions aiming to either delay or stop progression of vasculopathies are 
suboptimal, thus searching novel, targeted, risk-reducing therapeutic agents, or 
vascular grafts with full regenerative potential for patients with vascular 
abnormalities are urgently needed. Since first reported, pluripotent stem cells 
(PSCs), particularly human induced pluripotent stem cells, have open new 
avenue in all research disciplines including cardiovascular regenerative 
medicine and disease remodelling. Assisting with recent technological 
breakthroughs in tissue engineering, in vitro construction of tissue organoid 
made a tremendous stride in the past decade. In this review, we provide an 
update of the main signal pathways involved in vascular cell differentiation from 
human PSCs and an extensive overview of PSC-derived tissue organoids, 
highlighting the most recent discoveries in the field of blood vessel organoids 
as well as vascularization of other complex tissue organoids, with the aim of 
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1. Introduction  
Vasculopathy is an umbrella term used to summarize a plethora of vascular 
diseases characterized by abnormalities of the vasculatures. These 
pathological anomalies are often associated with a variety of risk factors or as 
a direct result of pre-existing conditions including diabetes, rheumatic diseases, 
livedoid vasculopathy, and systemic sclerosis. Vasculopathy is the key 
underlying cause of cardiovascular disease (CVD), which is the prevailing 
cause of mortality in modern society, accountable for more than 36% of all 
deaths worldwide1. Current mainstream pharmacological interventions aim to 
either delay or stop progression of vasculopathies and subsequent high-risk 
cardiovascular events2. Despite extensive clinical usage and compelling results 
from both pre-clinical and clinical studies, a gap of knowledge yet remains with 
regard to the precise mechanisms of most therapeutic interventions, not to 
mention the risk profile associated with long-term exposure of various 
preventative drug therapies, complexed by a myriad of patient-to-patient 
inconsistencies that might inevitably lead to contradicting treatment outcomes3. 
Thus, the introduction of novel, targeted, risk-reducing therapeutic agents for 
patients with vascular abnormalities pose a considerable challenge for the 
advancement of vascular disease prevention, treatment and healthcare.  
Over the past decades, the world had come to appreciate the power of modern 
technologies which had enabled advancements in uncovering the biochemical 
bedrocks of vascular diseases. The revelation that specific biological signalling 
pathways facilitating pathophysiological events had driven extensive 
mechanistic studies toward targeted treatments and drug development. For 
instance, endothelial dysfunction, inflammation and lipid infiltration were initially 
believed to be the precursors of atherosclerotic lesions4, however, the scope of 
the problem was greatly underestimated as countless follow-up studies 
revealed an elaborate, interwoven network of communications between 
different cell types, signalling molecules and downstream effectors5, with many 
still under debate for their validities. Moreover, identification of novel biomarkers 
for diagnostics and targeted therapies is an arduous process that also demands 
tremendous efforts from the current experimental models, which unfortunately 
has become somewhat obsolete in many aspects. 
Traditionally, scientists have relied on in vitro systems to conduct mechanistic 
studies at a cellular/tissue level. The simplistic, cost-effective nature of in vitro 
setups had become well-integrated by most fields of biochemical research, yet 
many do agree unanimously to the rhetoric that primary or immortalised cells 
differ tremendously from their tissue-level counterparts, therefore do not reflect 
normal cellular behaviours in their naïve microenvironments6. In vivo and ex 











enabled researchers to recreate key pathophysiological events whilst 
assessing multiple influencers at once, and most importantly, to observe 
systemic changes within a live organism. However, most animal models suffer 
from poor translatability because of the intrinsic differences in physiological 
characteristics between human and other organisms, which have led to 
inconsistencies that are detrimental for translating pre-clinical findings into 
meaningful clinical outcomes7. Consequently, to guarantee reproducibility and 
translatability in vascular research, more innovative, reflective and 
sophisticated modelling techniques are required to overhaul current established 
systems.   
The first human pluripotent stem cell (hPSC) line, more specifically human 
embryonic stem cell (hESC), was prominently introduced in 19988. Due to its 
huge potential to self-renew indefinitely and differentiate into any desirable cell 
type under controlled laboratory settings, hESC has been highly applicable in 
many research disciplines. Although this potential was realized shortly after, 
many researchers avert their eyes due to concerns over ethical issues, immune 
rejection, availability and patient-specificity. However, with the emergence of 
human induced pluripotent stem cell (hiPSC) technology9, it is now possible to 
obtain an unlimited source of patient-specific hiPSCs devoid of any ethical and 
immunological concerns. Once established, hiPSC lines encompass all the 
essential characteristics of human hESCs without the need to sabotage human 
blastocysts, while remaining autologous and disease-specific to its patient-
origin; moreover, introduction of powerful gene-editing tools such as Zinc Finger 
Nuclease (ZFN), transcription activator-like effector nucleases (TALEN) and 
CRISPR-CAS9, together with hiPSC technology, brings new insights to the 
pathophysiological roles of disease-related genes, and facilitates discovery-
driven, high-throughput drug screening without the concerns for cell availability.  
Joining forces with recent technological breakthroughs in the field of tissue 
engineering, in vitro construction of tissue mimetic via a combination of scaffold 
materials, key growth factors and hPSCs10, breathed new life into an otherwise 
stagnant monolayer culture system that was widely adopted in most early stem 
cell research. By virtue of incorporating critical biophysical cues such as 
dimensionality, stiffness and tomography11, three-dimensional (3D) culture 
systems far outclass traditional 2D systems in translatability and scalability, as 
many have found success from small-scale tissue reconstruction, including 
skeletal muscle fibres12, vascular grafts13, cartilage tissues14 and Organ-On-A-
Chip15, to large-scale reconstruction of organs with de-cellularized extracellular 
matrix (ECM) scaffold and hPSCs16. In this Review we will seek to examine the 
more recent discoveries in hPSC-derived vascular cells and blood vessel 
organoids, with particular emphasis on the newly reported key signalling 
pathways governing vascular cell specification and most recently established 











complex tissue organoids. 
 
2. Vascular cell specification and tissue engineering 
Vascular mural cells (MCs) and endothelial cells (VECs) are the two main 
functional cell types within human blood vessels (Figure 1). MCs can be further 
categorized into vascular smooth muscle cells (VSMCs) and pericytes. VSMCs 
are predominantly located in the middle layer of most arterioles and all arteries, 
whereas pericytes are most frequently found to reside along abluminal side of 
VECs that line the luminal surface. The phenotypic and functional identities of 
these vascular cells are pre-determined and are guided by spatiotemporal 
activation of particular signalling pathways at early embryonic development17-
20. 
 
2.1. Vascular cell differentiation from human PSCs  
Based on key discoveries in embryonic vascular development, three well-
accepted methods have been established for the generation of vascular cells 
from hiPSCs (Figure 2): 1) hiPSCs were first differentiated into neural crest 
stem cells (NCSCs) by fibroblast growth factor 2 (FGF-2) treatment 21, 22, then 
matured into VSMCs by seeding the NCSCs onto a relative stiff matrix, which 
were maintained in serum-free media containing transforming growth factor-β1 
(TGF-β1), as a result, the matured VSMCs exhibited enhanced mechanical 
properties23; 2) hiPSCs were differentiated into mesoderm following the 
treatment of bone morphogenic protein 4 (BMP4) and GSK3 inhibitors 
CHIR99021/CP21, the mesoderm was then treated with vascular endothelial 
growth factor (VEGF) and Forskolin to induce VECs specification; alternatively, 
by using platelet-derived growth factor-BB (PDGF-BB) and Activin-A to induce 
VSMC specification24. As a result, the induced VECs and VSMCs were 
comparable to primary cells in transcriptomes, metabolomic profiles and 
functional properties, as well as drastically reduced differentiation period in 
contrast to previous study25; 3) instead of traditional static culture set up, the 
introduction of dynamic forces, such as shear stress, combined with VEGF and 
FGF treatments, can accelerate VEC specification and yield a greater number 
of tube-like network; in particular, the improved maturation of VECs was 
accompanied by upregulated Notch1 signalling and F-Actin filament re-
aglinment by media flow26. It is worth noting that the response of iPSC-induced 
VECs to shear stress was different from human umbilical artery/vein endothelial 
cells, as distinguished by specific marker gene expressions27; overall, external 
mechanical stimuli can help facilitate the maturation of iPSC-derived VECs.  











sharing several intrinsic similarities in culture methods, there are fundamental 
differences which could be reflected in the time of establishment, 
phenotypic/functional differences in matured vascular cells and their potentials 
in clinical applications. In terms of timeline, protocol 1 was reported in 2015, 
followed by protocol 2 in 2019, and protocol 3 in 2020. The establishment of 
later protocols was somewhat inspired by the previously established protocols, 
for example in protocol 2, VSMCs and VECs were efficiently and rapidly 
induced using monolayer-directed differentiation method that is more time- and 
cost-efficient, whilst being accessible for most laboratories28 comparing to 
embryoid body (EB) formation; however, since the induced vascular cells were 
generated in static media in vitro, meaning a lack in any forms of biophysical 
stimulations, which is an important functional parameter for real blood vessels. 
In addition, there was no distinction between arterial and venous VECs in 
protocol 2, where the induced cells were far less capable in mechanical 
durability and therefore unsuitable for clinical usage. To circumvent this 
drawback, protocol 3 incorporated distinctive magnitudes of shear stress in 
addition to in vitro culture setup, correspondingly, it was found that shear stress 
also played an important role in specification of mouse iPSCs towards venous 
or arterial ECs, as evidenced by upregulated marker expressions for general 
VECs and arterial ECs, elevated level of nitric oxide secretion and parallel 
alignment of VECs to the direction of the laminar flow26. Nevertheless, protocol 
3 was predominantly an in vitro differentiation strategy, where iPSCs are of 
mouse origin and the induction of VSMCs was not included; whereas protocol 
1 encompassed both cyclic circumferential stretching and in vivo biological 
environment as two co-existing factors to induce VSMCs from human iPSCs. 
The induced VSMCs exhibited enhanced mechanical strength and more 
durable vascular grafts23. As for the growth factor combinations deployed for 
each protocol, there are no studies confirming which combination is the most 
optimal. Importantly, it is worth mentioning that these vascular cells generated 
from PSCs in these three protocols were still fraught with numerous intrinsic 
limitations including cell-to-cell and line-to-line heterogeneity, as well as 
functional, metabolic and biological immaturity of these hPSC-derived cells. 
Therefore, these protocols are still confined in generating differentiated 
vascular cells, albeit with adequate morphologies and acceptable functional 
capacity, are not ready for generating in vivo self-assembling vessels or 
creating in vitro engineered vascular grafts yet. In conclusion, more research 
has yet to be done before the wide-spread adoption of cell-based therapeutic 
strategies can take place in clinical application.  
 
 











Naturally, the transition from PSCs into VSMCs and VECs encompasses many 
signalling pathways that facilitate stem or progenitor cells to commit into a 
specific lineage, and ultimately mature into vascular cells. Knowledge of these 
underlying signalling mechanisms is therefore crucial for designing in vitro 
induction protocols, whether to construct tissue-engineered vascular graft 
(TEVG) or blood vessel organoid (see later section). In this section, we mainly 
focus on the most recent updates on two vital signalling pathway, Notch and 
Wnt (Table 1) and their involvements in vascular differentiation, whereas others 
such as TGF-β1, PDGF-BB, serum response factor, retinoic acid, small 
GTPase RhoA, reactive oxygen species29-31, VEGF, TGF-β/BMPs32, 33, histone 
deacetylases34-37, micro-RNAs38-40, matrix metalloproteinase41-43, and 
extracellular matrix-integrin signalling44, will not receive many attentions as they 
have already been elucidated comprehensively in previous reviews45-53. 
 
2.2.1. Canonical Notch signalling pathway 
Canonical Notch is a highly conserved signalling pathway that plays a crucial 
role in MC and VEC specification54, as evidenced by disruption of Notch 
signalling can lead to failure in arterial lineage commitment, malformation of 
vascular network and even embryonic lethality20. Notch3 is most predominantly 
expressed in MCs, where a loss of function mutation in mouse embryonic cells 
can result in stepwise disruptions of arterial VSMCs55-57. Additionally, it was 
shown in zebrafish that Notch3 upregulates MC proliferation, and activation of 
different Notchs, such as Notch2 and Notch3, in the mesenchyme precedes 
MC specification in a region-specific pattern58, 59. In other words, diverse 
signalling effects can be achieved through different Notch receptor-ligand 
binding pattern. For example, Delta-like4 and Jagged1 are two reverse Notch 
ligands involved in angiogenesis, depending on their glycosylation status60. 
Delta-like4 may also influence the differentiation of pericytes from skeletal 
myoblasts61. Similarly, the intracellular domain of distinct Notch receptors may 
elicit different response when bound to the promoters of target genes62. On the 
other hand, Notch1 and Notch4 are mainly involved in VEC development. 
However, upon vascular injury, Notch1 and Notch3 instead play an important 
role in mature VSMC phenotype modulation63-65 and VSMC differentiation from 
adventitial stem/progenitor cells41. It is understandable that Notch receptors 
and ligands are expressed in advance by signalling cells that subsequently 
participate in Notch signalling. However, it remains unknown if these molecules 
are simultaneously upregulated in vascular cells and/or other cells within 
arterial vessels, prior to Notch signalling activation during vascular 
development and arterial remodelling. 











Wnt signalling pathways are divided into canonical (β-catenin dependent) and 
non-canonical (β-catenin independent) pathways. Canonical Wnt signalling 
pathway is highly conserved, and plays an irreplaceable role in maintaining 
stem cell function, cell fate specification, tissue homeostasis and organ 
development66, 67, as well as in vascular cell specification. Notably, the 
functional involvement of Wnt signalling at different stages of embryonic 
development has not been entirely clear. As for mammals, the specification of 
somatic vascular cells normally undergoes four phases: undifferentiated PSCs, 
primitive streak, ectodermal neural crest or mesoderm, and somatic cells. The 
first step of PSC differentiation is the formation of primitive streak, where PSCs 
give rise to all endodermal and mesodermal lineages68. At this early stage of 
mesodermal development, transcript level of Wnt3 gene, along with Brachyury 
(T), eomesodermin (EOMES), FOXA2, MIXL1, and MESP1, are upregulated, 
all of which coordinate the induction and patterning of mesoderm68. Additionally, 
Wnt signalling pathway combined with BMPs, Activin/Nodal and FGFs, are 
momentous inducers for mesoderm formation68, 69. More specifically, during the 
process of mesodermal induction from hPSCs, activation of β-catenin 
dependent Wnt signalling pathway by GSK3 inhibitors (CHIR99021 or CP21) 
and BMP signalling via BMP4 protein, push PSCs to commit into mesodermal 
lineages, enabling downstream vascular lineage specifications24. The vital role 
of Wnt signalling pathway in facilitating mesoderm induction has been 
extensively studied, however, there are less studies on Wnt signalling-regulated 
vasculogenesis. More recently, a study has found that for human ESCs, the 
activation of Wnt signalling by GSK3 inhibition after mesodermal induction 
increased formation of vessel-like network, as well as the number of matured 
VECs70. They also reported that the over-expression of Wnt3a could lead to 
increased number of mature VECs, which was mediated by auto-upregulated 
transcription factor, Lef1, whereas the over-expression of Wnt8 was shown to 
impact the size of VECs70.  
2.2.3. Other important signalling pathways  
Sonic hedgehog (Shh) is an important component of the hedgehog family, it 
was demonstrated in zebrafish that Shh signalling pathway is crucial in lineage 
commitment of endothelial progenitors to form artery20. A communication model 
for Shh and Notch signalling was proposed as to be the underlying mechanism 
of arterial cell maturation71. Specifically, Shh initially binds to the G protein–
coupled receptor Smoothened (SMO) and transmembrane receptor Patched 
(PTC), then it indirectly induces VEGF production in nearby somite, which 
subsequently activates Notch signalling pathway to boost arterial induction in 
zebrafish72-75. Nevertheless, whether the same signalling interplay takes place 
in mammals is yet to be determined. Hippo signalling pathway, an extremely 











modulating cellular growth, organ size and other functions. Hippo signalling 
pathway plays an important role in injury-induced arterial remodelling. When 
the carotid artery is injured, the expression level of Yap is dramatically 
upregulated in VSMCs which in turn, promotes proliferation and migration of 
VSMCs76. Moreover, an important role for Hippo signalling pathway in 
developmental and pathologic lymphangiogenesis77, 78, angiogenesis79, SMC 
differentiation80, and coronary vasculature development81 has been well-
documented in the literature. 
2.2.4. Cross-talks between Wnt and Notch signalling pathway 
Although canonical Notch signalling pathway is highly conserved and self-
contained, it may also exert other signalling effects beyond its original role82-85 
by cross-talking with other signalling pathways. For example, a study showed 
that membrane-bound Notch can cross-talk with Wnt signalling pathway and 
down-regulate the cytoplasmic level of unphosphorylated (activated) β-catenin 
protein in stem and colon cancer cells, by directly interacting with active β-
catenin86. Additionally, during cerebrovascular VEC development, activation of 
the canonical Wnt signalling pathway can influence the amount of 
monocarboxylic acid transporter 1, which mediates the transportation of 
monocarboxylate fuels for brain VECs; whereas inhibition of the Notch 
signalling via γ-secretase inhibitor antagonize the up-regulation of 
monocarboxylic acid transporter 1, further supporting the functional importance 
of the cross communication between the canonical Notch and Wnt signalling 
pathway in VEC development87. 
 
2.3. PSC-based tissue engineering vascular graft (TEVG)  
Clinically, autologous and allogenic graftings are primarily limited by the narrow 
availability of native human blood vessels88, 89. However, ever since the 
introduction of vascular constructs built from biocompatible materials, synthetic 
vascular graft gradually rose to popularity as a main-stream player in most 
vessel-replacement therapies. Nonetheless, due to several post-operative 
concerns such as intimal hyperplasia, restenosis, immunologic rejection and 
post-operative infection89, 90, further improvement or alternatives are urgently 
needed. Fortunately, the emergence of tissue engineering technologies have 
brought about new insights into circumventing these existing challenges89. 
Vascular engineered constructs are artificial blood vessel tissue mimetics that 
encompasses adequate mechanical durability, protein synthesis and cell types 
comparable to the naïve human vessels. Over the decade, numerous platforms 
have been developed with the aim to steadily produce patient-compatible 
TEVGs (Figure 3). 











generate clinically applicable tissue engineered vascular constructs by casting 
the 3D hydrogel matrix onto the decellularized porcine small intestinal 
submucosa fixed in a custom-made metal frame. Human adipose tissue-
derived stromal cells (hASCs) and five different types of hVECs (HUVECs, 
human umbilical vein endothelial cells; hCEC, human cardiac endothelial cell; 
hPAEC, human pulmonary artery endothelial cell; iCell-ECs, iPSC derived 
endothelial cells from Cellular Dynamics International; hiPSC-ECs, human 
iPSC-derived endothelial cells) were co-cultured within the 3D hydrogel matrix. 
All co-culture systems demonstrated capacities to self-assemble and 
spontaneously form vessel-like networks which featured with small diameter 
lumens within the 3D hydrogel91 (Figure 3A). Meaningfully, this study brought 
new insights to the generation of TEVGs, which not only featured five types of 
hVECs, but also introduced an alternative mural cell hASCs, apart from SMCs 
and pericytes. Although hASCs are easily obtained from subcutaneous fats of 
patients, which mitigates the issues of cellular availability and immunogenicity 
against host92, the patients whom undergo this procedure are typically senior, 
with higher abundance of somatic cells exhibiting reduced proliferative 
capacities, comparing to younger patients; Secondly, the utilization of animal 
product as scaffolding materials still remained a huge drawback. Matrigel for 
example is still a controversial subject in clinical studies due to its batch-to-
batch inconsistent immunogenicity and composition. Thus, the clinical adoption 
of this therapeutic strategy is still pending for extensive investigations. 
Additionally, a recent study has also found that by co-culturing of iPSC-derived 
VSMCs and VECs under atheroprone hemodynamic context, the matured cells 
were highly similar to primary VSMCs and VECs93; In another study94, hiPSC-
derived VSMCs (hiPSC-VSMCs) were seeded onto a biodegradable scaffold 
and incubated under defined physical cues, more specifically, incremental 
increase of pulsatile radial distention at 110–120 beats/minute. The resulting 
hiPSC-VSMCs-based TEVG was engrafted into a nude rat, which remained 
patent after 4 weeks, with no longitudinal extension, radial dilation or teratoma 
formation, thus demonstrating excellent mechanical strength, durability and in 
vivo stability. Apart from radial distention stress, shear stress also plays a vital 
role in promoting iPSCs differentiation into VECs and facilitating VEC 
maturation.  
Although hiPSCs can be readily reprogrammed from somatic cells of either 
patients or donors, several impeding factors are in play, such as difficulties in 
obtaining reprogrammable cells from patients with advanced age, time spent 
on laboratory procedures, and reduced effectiveness of cell-based therapy for 
patients with genetic disorders, altogether hindering the application of hiPSC 
technology in clinical practices. To circumvent these challenges, two novel 











immunologic tolerance phenomenon between the maternal immune system 
and paternal antigens during pregnancy95, researchers96 are now able to 
produce hypo-immunogenic iPSC from other young, health donors; more 
specifically, it was found that the syncytiotrophoblast cells, which constitute the 
interface between foetal tissue and maternal blood, express low level of major 
histocompatibility complex (MHC) class I and II, but up-regulated expression of 
CD47. CD47 is an omnipresent membrane protein that impedes phagocytosis 
by interacting with multiple cell surface receptors97. Based on these findings, 
Deuse et al96 adopted a versatile gene-editing tool, CRISPR-CAS9, to knock 
out β2-microglobulin (B2m) gene, a configurational component of MHC class I, 
and Ciita gene, the primary modulator of MHC class II genes98, followed by the 
insertion of Cd47 gene sequence via lentivirus transfection. The 
B2m−/−/Ciita−/−/Cd47-expressing hiPSCs featured hypo-immunogenicity with 
full developmental capacities96. Building on this, the usage of this hypo-
immunogenic hiPSC in vascular graft should minimize host immune rejection, 
as well as efficiently prevent coagulation and restenosis post-implantation. 
Notably, this breakthrough in iPSCs technology can offer healthy, vigorous 
pluripotent cells to senior-age patients, or patients with inherent genetic deficits 
or systemic diseases; 2) Gene-editing tool can be utilized to correct the gene 
deficits in patient somatic cells, then reprogrammed to patient-specific iPSCs 
devoid of defective gene copies. In recent years, the revolutionary CRISP-
Case9 system has been increasingly used for efficient gene manipulation of 
embryonic cells, somatic cells or gametes99. Specifically, CRISPR/Cas9, a 
RNA-guided nuclease system, is far superior to other gene-editing tools, with 
low possibilities of non-specific targeting or incomplete suppression of the 
target genes, while showing significant improvements in precision for gene 
editing in hiPSCs100, 101. 
Although vascular tissue engineering technologies have shown many promises, 
more systemic assessments are needed before the wide-spread application of 
TEVGs into clinical practice, such as mechanical durability, physiological 
functions, compatibility to host, cell plasticity, spatial-temporal degradation rate 
and cost-efficiency. More specifically, long-term in vitro cell culture may result 
in the gradual loss of cellular identities20, 102, hence is more likely to induce cells 
with weaker functional capacities and higher heterogeneity comparing to their 
in vivo counterparts. Additionally, vascular cell specification and maturation are 
closely influenced by environmental cues, as the absence of which may lead to 
complicated epigenetic and genetic changes23, 93. It is also dreadfully difficult to 
accurately control cell growth conditions in a correct time frame to recreate in 
vivo events. Moreover, with respect to the stage of cell development, the VECs 
in TEVGs are matured, therefore when engrafted, the plasticity of the 
engineered vessel is low and the integration with host blood vessel is less 











surgeries may cause blood anastomosis. Nevertheless, despite the countless 
technical improvements in experimental designs, tissue engineering 
approaches in general, does not faithfully recapitulate vessel development due 
to insufficient multicellular communication and hemodynamic interactions which 
provide critical clues for vascular development in naïve biological system. 
 
3. A new perspective: vascular organoids 
3.1. Organoid technologies hold enormous potentials in 
clinical research and regenerative medicine 
Organotypic technology represents a tremendous stride in the refinements of 
tissue engineering techniques. Owning to the organoid’s ability to self-organize 
under in vitro setups, it is now possible to generate stable, well-defined 3D 
structural mimics that resemble their in vivo counterparts in microstructures, 
cellular organizations and functional characteristics103. Comparing to traditional 
tissue engineering techniques, the advantages of using hPSCs/hiPSCs-derived 
organoids are: 1) highly versatile with downstream applications, 2) easy to 
visualize across all stages, 3) free of ethical concerns, 4) cost-effective, 5) 
ability to self-organize, 6) superior morphologies104, 7) remains genetically 
stable in long-term cultures105. 
To date, organoids have been successfully generated from hESCs106, 
hiPSCs107, resident progenitor cells108 and patient-derived cancer cells109. 
Research platforms that utilized healthy organoids have revealed key 
information of organ-specific developmental pathways which were previously 
difficult to obtain with most in vivo models, such as the role of FGF signalling in 
gut formation110, the role of SHH signalling in lung-specific cell fate 
determination107, and fate-mapping of neural stem cells during brain 
development111. Alternatively, with disease-specific organoids derived from 
either patients or genetically modified cells, researchers were able to conduct 
mechanistic studies on disease progression, identifying disease-related genes, 
and assessing drug toxicity/efficacy in a high-throughput manner, as 
demonstrated in a recent study that outlined the causal link between infectious 
disease and microcephaly using brain organoid112, or another study which 
predicted gene-associated drug response in cystic fibrosis patients113. However, 
despite being met with overwhelming enthusiasm by most of the research 
communities, organoid-based research is still at the fetal stage of development 
and is faced with numerous practical challenges. Whether organoids can truly 
become the ‘game changer’ in regenerative medicine that many have 
envisaged is still an open question. 











regenerative medicine, as an alternative to tissue/organ engraftments for 
patients who had sustained non-recoverable loss of vital organs. Although 
conceptually promising, the efficacy and long-term safety of organoid-based 
therapies are still pending evaluation due to insufficient human studies; in other 
words, the wide-spread clinical integration of organoid technologies for tackling 
degenerative diseases still faces significant constraints (Table 2). Most 
importantly, the production of human organoids has to be in compliance with 
good manufacturing practices (GMP) criteria, that are universal for all clinical 
products114 prior to clinical utilizations. In any case, organoid-based 
regenerative studies are to be further expanded and diversified in spite of the 
remarkable progress thus far. The positive results produced by animal-based 
organoid transplant models such as colon epithelium115, cerebral cortex116 and 
liver lobules117, indeed make attractive headlines and fill the hearts with 
overwhelming confidents, but we still face numerous obstacles before the full 
potential of organoid technologies are harnessed. 
3.2. The making of vascular organoids 
During embryonic development, formation of the circulatory system precedes 
other system developments in all vertebrate embryos118. The need for 
transporting nutrients and expelling waste heavily outweighs the rest, since 
passive oxygen diffusion is no longer capable of sustaining rapid fetal growth 
during late-gastrulation119. Vasculogenesis and angiogenesis are crucial 
processes that govern the development of embryonic vasculatures. Whereas 
vasculogenesis describes the de novo formation of primary capillary plexus 
from the fusion of blood islands - small aggregates of endothelial precursor cells 
that are able to form a hierarchical networks of primitive blood vessels120, 
angiogenesis describes the refinement of the vasculatures, via extensive 
remodelling and expansion of capillary networks, thus promoting the formation 
of a mature circulatory system121. By the same token, reconstruction of blood 
vessel-like structures ex vivo is a comparable process to normal vascular 
development, where the end-product should adequately recapitulate structural 
organizations of innate vasculatures, sufficient in functional capacity for 
carrying out physiological roles, and promote host tissue integration without 
adverse effects122. 
Drawing inspirations from established 2D induction methods and 3D co-culture 
assays, Wimmer et al streamlined their approach and designed a multi-step 
protocol that successfully gave rise to hPSC-derived vascular organoids in vitro 
(Figure 4), without the need to independently induce and purify multiple 
populations of homogenous vascular cells. Structurally, hPSC-derived vascular 
organoid forms a self-contained, interconnected 3D microvascular network 
composed of VECs, pericytes and a continuous layer of basement 











directed toward the mesodermal lineage via Wnt activation and BMP4 
stimulation, followed by uninterrupted VEGF-A and Forskolin treatments for 
vascular lineage specification24. Instead of starting off with hPSCs in monolayer 
cultures, Wimmer et al selected ultra-low attachment plates which allowed 
hPSCs to self-aggregate. When embedded within 3D collagen I–Matrigel gels, 
these hPSC aggregates were able to develop into stable, branching, vessel-
like endothelial networks under the treatment of VEGF-A, FGF-2 and Fetal 
bovine serum (FBS). Amongst many highlights, there were several key findings 
that took the spotlight: 1) isolated vascular organoids could be maintained 
individually in 96-well plate for a long duration, 2) in vivo transplantation 
confirmed excellent vascular integration, and demonstrated incredible stability 
for >6 months post-transplantation in SCID mice, 3) upon dissection, lumen-like 
cavities were observed within sprouting microvasculature, as well as vessel-
like cellular organizations where VECs formed luminal cavity, tightly associated 
with pericytes and enveloped by an outer layer of ECM proteins, 4) vascular 
organoids were composed of multiple cell types, including pericytes, VECs, 
mesenchymal stem-like cells and haematopoietic cells, 5) organotypic cultures 
displayed excellent angiogenic potentials, 6) microvasculature formation was 
observable despite using a small number (n=2-5) of vascular organoids. 
Undeterred by the simplicity and efficiency of Wimmer et al ’s methodology, one 
glaring constraint, which also happens to be a major bottleneck for the majority 
of organotypic differentiation protocols124, was the issue with reproducibility and 
scalability; more specifically, the formation of hPSC-aggregates (EB formation) 
in static suspensions was undoubtedly a great starting point for downstream 
lineage specifications, whilst providing the hPSCs with the highest level of 
organizational freedom, as well as rich intercellular communications; however, 
there were no additional measures implemented during the early stages of 
differentiation, in order to reduce the likelihood of unwanted cellular 
heterogeneity. The absence of cell-sorting procedures also does not bode well 
for the overall reproducibility of the protocol, thus, the incorporation of technique 
such as fluorescence assisted cell sorting would greatly benefit the overall 
scalability and reproducibility of this protocol; additionally, the protocol did not 
address the implementation of a robust quantitative quality control step, which 
is necessary to meet GMP standards and should be put in place as a way to 
combat the potential impacts of interexperimental or intercolonial variations125. 
In any case, the establishment of a rigorous quality control guideline is key for 
fulfilling the overall potentials of vascular organoid technology in both clinical 
research and therapeutic applications.  
 











A lack of vascularization has always been a major roadblock for de novo 
generation of functional, viable biomimetic tissue constructs that are suitable 
for clinical and research applications. Consequently, vascularization strategies 
were incorporated for the purpose of circumventing growth arrests commonly 
seen in large organotypic cultures. Under the absence of de novo vasculatures, 
the generation of a functional organ is often impeded by the formation of 
necrotic cores, and subsequent loss of proliferative capacities126. In light of 
recent technological advancements in the field of tissue engineering, 
construction of in vitro vasculatures at various scales can be achieved by a 
variety of techniques, including 3D bioprinting, sacrificial networks, 2-photon 
fabrication, subtractive fabrication and many more127. While state-of-the-art bio-
fabrication techniques can impose appropriate structural patterns for organoid 
vascularization, Wimmer et al provided a simplistic hPSC-based platform that 
are capable of giving rise to self-organizing, vascularized organoids in vitro; 
similarly, Pham et al also achieved tremendous success in establishing highly 
vascularized, self-organizing brain organoids by co-culture with VECs derived 
from patient iPSC with remarkable longevity128. Here, we briefly discussed the 
recent advancement of vascularization of complex human organoids using 
hPSC-based vascularization strategies (Figure 5). 
3.3.1. Vascularization of human cerebral organoids 
Whole-brain organoids were first introduced by Lancaster et al, although the 
organoids could remain viable for over a year under controlled environment, 
absence of vasculature formation directly contributed to its lacklustre expansion 
capacity, as well as inadequate neural tissue patterning129 (Figure 5a). Whilst 
it has been proven that the established cerebral organoids is capable of 
integrating into host brain tissue, generating functional microvasculatures, 
neuronal tissues, and even producing synaptic activities130, the inclusion of 
mouse as host environment for vascularization does not necessarily translate 
to other host organisms. To overcome this, Pham et al re-embedded the non-
vascularized cerebral organoids generated from hiPSCs with 250,000 ECs 
derived from the same hiPSC line (Figure 5b); as a result, robust 
vascularization of re-embedded organoids was observed after 2 weeks, as 
demonstrated by robust infiltrations of CD31+ cells into the cerebral organoids 
and subsequent formations of tubular structures within these organoids. 
Consequently, vascularized cerebral organoids demonstrated superior 
survivabilities in vivo and deep penetrations into the STEM121+ core region, 
which were absent in non-vascularized organoids. Similarly, Wörsdörfer et al 
established a hiPSC-based co-culture method that encouraged formation of 
heirachical, branching vascular structures within iPSC-derived Sox1+ neural 
spheroids131 (Figure 5c). Upon close inspection, it was reavealed that iPSC-











spheroids and gave rise to mesenchymal tissues, which later matured into 
sprouting endothelial networks comprised of CD31+ VECs, finalized with lumen 
formation as well as recruitment of periendothelial cell (resembling 
myoendothelial junctions132. Morevoer, Cakir et al vascularized human cortical 
organoids by incorporating ETV2 (human ETS variant 2, a transcription factor 
when ectopically expressed can induce endothelial differentiation133)–
overexpresing human VECs into early embryoid body cultures (Figure 5d). 
Whereby the presence of ETV2-expressing cells on day 18 had greatly 
enhanced the formation of vasculature-like structures during subsequent neural 
and endothelial differentiation, with improved functional characteristics as 
observed in the mature microvascular assemblies134. It should be noted that 
although these strategies achieved vascularization via different approaches, 
they are principally similar in differentiation methodologies – directed 
differentiation that also incorportated other cell types. The advantages are of 
course the freedom of controlling external stimuli while allowing intercellular 
communications between different cell types; however it should be noted that 
co-culture organotypic setup may result in restricted access to external 
differentiation factors135; the use of genetically modified hPSC may also have 
subtle ramifications in organoid functions, or gene expressions profiles, which 
should be scrutized under rigorous quality control procedures. 
Last but not least, Ham et al generated blood vessel-like networks within iPSC-
derived cerebral organoids in absence of iPSC-derived progenitors cells, 
displaying outstanding architectural, functional and biochemical characteristics 
similar to that of blood-brain barrier seen in live organisms (Figure 5e). This 
was achieved by incorporating human recombinant VEGF during embryoid 
body culture and neural differentiation, followed by a 2-month treatment of 
Wnt7a in the presence of VEGF, which had successfully induced vessel 
maturation and microvascular-network infiltration in cerebral organoids136. 
However, although the strategy offered cell-type diversity with some degree of 
chemical-based control, the unpredictable nature of allowing EB formation at 
early differentiation stage means high variability and heterogeneity, which might 
present at some point of organoid development and pose a significant 
challenge for achieving large scale reproductions.  
 
3.3.2. Vascularization of human kidney organoids  
Analogous to the brain, kidneys also require extensive vascular networks in 
order to achieve functional competence and homeostasis. Whereas previously 
established protocols may excel in generating iPSC-derived renal organoids 
with distinguishable, nephron-like 3D organizations of renal cells in static in vitro 











maturation remained fundamental challenges for deriving functionally mature 
renal organoids. Despite evidences of endothelial cells being detected inside 
established renal organoids140, an absence of blood vessel-like organization of 
vascular cells indicated no meaningful glomerulus infiltration or tubular 
compartmentalization, effectively, zero functionality.  
Interestingly, Homan et al employed a dynamic culture setup that could 
generate vascularized renal organoids with perfusable lumen space, consisting 
of PECAM1+ mature endothelia and recruited PDGFRβ+ pericyte-like MCs141. 
By semi-embedding developing renal organoids onto a gelatin-fibrin (Gelbrin)-
coated millifluidic chip, Homan et al were able to observe markedly improved 
tubular epithelia maturation, glomerular vascularization and overall functional 
maturation of kidney organoids, comparing with the original hPSC-based 
method reported by Morizane et al142. Despite this flow-enhanced 
vascularization being achieved with only a collection of defined chemo-
mechanical parameters, additional signalling components may still be required 
to ensure stable generation of perfusable renal vascular network. Moreover, 
this protocol showed no meaningful coordination in patterning of different 
nephron cell components during organoid development, marking a stark 
contrast to normal kidney development in vivo. 
Recently, Low et al introduced a static induction platform that could robustly 
generate vascularized renal organoids via dose-dependent exposures to Wnt 
signalling activator, GSK3 inhibitor CHIR99021, at different stages of organoid 
differentiation143. Specifically, following the induction of intermediate mesoderm 
(IM) progenitors, Low et al adapted two medium recipes, namely in addition to 
50 ng/mL FGF9 (basal medium), 3 μM or 1 μM CHIR99021 were also 
supplemented chronologically. The differentiation medium containing 3 μM 
CHIR99021 were used to ‘prime’ the IM for lineage commitment (termed 
‘Priming CHIR’) for two days, 1 μM CHIR99021 were then supplemented in the 
basal medium at day 14 of differentiation, which were then ‘pulsed’ for a 
duration of 1-10 days (termed ‘Patterning CHIR’). As a result, the final 
organoids at day 24 exhibited remarkable proximal-distal patterning of kidney 
tissues, as well as sufficient infiltrations of vasculatures comprised of 
CD31+/CD34+ endothelial cells143. However, similar to the conundrums faced 
by human brain organoids, the concerns regarding the overall reproducibility 
and scalability of static, unguided differentiation methodology persists.  
3.3.3 Vascularization of other human organoids 
In addition to human cerebral and kidney organoids, other complex organotypic 
models such as human cardiac, liver, pancreatic and intestinal organoids could 
also benefit from increased cellular complexity. The two most common 











inclusion of appropriate supporting cell types or exposures to in vivo 
environments could enhance organoid complexities, when compared to 
traditional mono-culture setup144; these approaches are often implemented for 
most vascularization strategies of other human organoids.  
For example, conventional hPSC-derived cardiac organoids were obtained 
through EB-mediated cardiac differentiation, which often suffered from poor 
spatial arrangements of cardiomyocytes (CMs) and stromal cells, as well as 
lacking capillary network formation due to the absence of biophysical stimuli145. 
Instead, when hPSC-derived CMs (hPSC-CMs) were mixed with ventricular 
cardiac fibroblasts and HuVECs at a ratio that similar to the cell ratios in 
developing hearts (5:4:1) and seeded onto a micro-fabricated insert with 
appropriate biophysical parameters, the cardiac organoids closely resembled 
native tissue architectures, forming microvascular networks comprised of 
CD31+ VECs, while also exhibiting contractile and electrophysiological 
properties when matured146-148. These newly developed and vascularized 
human cardiac organoids could be cultured in a 96-well format, with minimal 
requirement of tissue handling and allowing for real-time analysis of cardiac 
contractile parameters, thus enabling high-content screening of mature hPSC-
CMs, elucidating underlying mechanisms of human cardiomyocyte cell-cycle 
arrest, proliferation and apoptosis, predicting drug cardiac toxicology, and using 
as drug discovery pipelines to identify the most efficacious activators of cardiac 
regeneration149.  
For human hepatic organoids, many vascularization strategies abide by the 
same core elements – a Matrigel-assisted 3D co-culture of hPSC-derived 
hepatocytes, source of ECs and mesenchymal stromal cells (MSCs). 
Interestingly, the source of ECs may vary between human umbilical vein 
endothelial cells150, human adipose microvascular endothelial cells151 and 
hPSC-derived ECs152; whereas MSCs may vary from human bone marrow-
derived MSCs150, hPSC-derived MSCs153 to human dental pulp-derived 
MSCs154. In general, 3D co-culturing of hPSC-derived hepatocytes, ECs and 
MSCs could facilitate the in vitro self-organizations and subsequent 
maturations into hepatic spheroids, completed with self-contained 
microvascular networks comprising of CD31+ endothelial cells155. Additionally, 
transplantation of hepatic organoid into immune-compromised mice could 
promote further maturations of the CD31+ endothelial networks and improve 
overall tissue architectures156. Similarly, vascularized pancreatic organoids 
were generated by 3D co-culturing of human isolated islet cells, ECs and MSCs, 
embedded in scaffolding materials such as hydrogels; further maturations of 
the self-contained microvascular networks were observed post engraftments157. 
However, formation of microvascular networks was not observed when human 











as no endothelial networks were constructed158; last but not least, the 
vascularization strategies of hPSC-derived human intestinal organoids159 were 
strictly confined to in vivo models, more specifically, de novo formation of 
microvascular network was only observable in a form of host vessel integration 
160. 
3.4. Applications of vascular organoids technology in 
vasculopathies research 
One of the potential applications of vascular organoid cultures, as Wimmer et 
al described, is to study the pathophysiological development of diabetic 
vasculopathy, and to validate existing pharmaceutical interventions for this 
disease. To their surprise, the organotypic culture was able to faithfully 
recapitulate the thickening of the basement membrane of distal microvascular 
network – a pivotal pathological event of diabetic vasculopathy observed in 
human patients161. It was achieved by conditioning the organotypic cultures with 
a combination of inflammatory cytokines and high level of glucose. Further in 
vivo studies also confirmed similar microvascular abnormalities in host mice. 
Importantly, the 96-well organotypic cultures enabled high-throughput drug 
screenings and led to the subsequent discovery of critical signalling effectors, 
DLL4 and NOTCH 3, both are key drivers of the thickening of basement 
membrane commonly observed in diabetic vasculopathy162, 163.  
The implications of this approach are enormous (as shown in Figure 6). 
Keeping in mind that vasculopathies are manifestations of structural or 
functional ailments of either large or small blood vessels, a culture system that 
promotes formation of functional, vessel-like networks from an endless supply 
of precursor cells in vitro, can potentially revolutionize the field of vascular 
research. For example, healthy vascular organoid is ideal for mechanistic 
studies of pro-/anti-angiogenic factors, as insufficiency of angiogenesis cause 
disruption of normal vessel homeostasis, resulting in ischemia-related diseases 
such as myocardial infraction, vascular degeneration and neural 
degeneration164. Moreover, unmodulated angiogenesis is responsible for 
tumour growth, metastasis and evolution. Additionally, abnormal 
vascularization is also responsible for inflammatory disorders, atherosclerosis 
and blindness165. Furthermore, disease-specific vascular organoids derived 
from either patient or genetically modified hiPSCs can provide a robust, high-
throughput drug screening platform for personalized therapies. With rapid 
generation (11 days) and a 96-well culture format, a large number of patient-
specific vascular organoids can be generated simultaneously, enabling 
researchers to discern disease-related gene effectors, via a discovery-based 
approach. 











for its role as an initiator of development of atherosclerosis, hypertension, 
arterial stiffening and systemic vessel-related complications. Traditionally, in 
vitro assessment of endothelial functions are performed in monolayer cell 
cultures166 and whole-organ cultures167. Cell cultures are commonly used for 
discovering signalling pathways and characterisations of endothelial response 
to endothelium derived relaxing factors; whereas whole-organ cultures are 
often deployed for functional studies within the context of an organ. Despite the 
significant contributions made by whole-organ cultures throughout the past 
decades of vascular research, very little progress was achieved in regard to 
overcoming a number of deep-rooted flaws, including organ deterioration due 
to ischemia and lack of perfusion, difficulties in preserving organ functions, and 
overwhelming economic burdens. In recent times, applications of hiPSC/hPSC 
derived microvascular constructs in modelling endothelial functions have 
gained tractions, as more and more robust modelling techniques are being 
reported, including the human blood-brain barrier168, 3D microvasculatures169, 
and 3D vascularized renal tissue170. Organoid technologies are therefore highly 
applicable in modelling endothelial dysfunctions, measuring responses to 
vasoconstrictors/vasodilators, using either patient-derived iPSCs or gene 
edited iPSCs, in a rapid, high-throughput fashion. 
As described by Wimmer et al, transplantation of hiPSC-derived vascular 
organoid in immunodeficient, diabetic mice faithfully recapitulated key 
pathological event of diabetic vasculopathy in vivo. Thus, organotypic 
transplant can potentially serve as an efficient, highly versatile in vivo platform 
for prospective genetic studies of chronic vascular diseases, as well as 
modelling facets such as inflammation response, immune cell interactions, 
vessel permeability, lipid interactions, and vascular remodelling. Additionally, a 
standardized host model can provide retrospective evidence for drug efficacy, 
biomarker validities and other vascular disease-related parameters, or produce 
complementary results for a range of preclinical studies. 
 
4. Pressing challenges and future directions  
Although vascular organotypic technology represents a tremendous stride in 
generating patient-specific TEVGs, using hPSC-derived vascular cells or other 
cell types to create engineered vascular grafts and organoids in vitro is at the 
very early stages of development and far from being ready for clinical 
applications (Table 2). One of the major challenges of vascular organoid 
technologies is the lack of perfusion of blood under in vitro settings. 
Conventionally, perfusion of blood is only achievable via transplantation into a 











accumulation in long-term 3D cultures. The inclusion of perfused blood could 
drastically improve the longevity of vascular organoid cultures, as seen in renal 
organoid cultures. It could also incorporate key functional parameters of native 
blood vessels, as it is evident that haematopoietic cells, immune cells and 
circulating vascular progenitor cells all contribute to the homeostasis of vascular 
networks171. Mechanobiological forces created by blood perfusion are also 
equally important in maintaining the viability of vasculatures172. Moreover, since 
circulating bone marrow-derived cells, such as leukocytes and monocytes, are 
facilitators of the inflammatory responses localized around pathological lesions, 
as well as the systemic response hallmarked in atherosclerosis, inclusion of 
blood and/or selected immune cells in organotypic cultures could enhance 
translatability and provide responses that are more reflective of the naïve 
physiological environment, as demonstrated by Noonan et al in their tri-cellular 
2D cultures173. 
Cellular heterogeneity in organotypic cultures is frequently regarded as a 
significant improvement by most research communities. In actuality, a culture 
of heterogeneous population of cells and its subsequent response to drugs can 
be somewhat unpredictable and difficult to reproduce, even more so in case of 
vascular organoids, as evidenced by the fact that more than two subsets of 
cells were observed; conversely, the development of organotypic cultures with 
varied cellular compositions, such as cardiac tissues, can be extremely 
challenging due to the complexities of functional cell types and relevant spatial 
organizations174, the precise ratios of each heterogeneous populations175, 
differences in transcriptomes between hPSC-derived cardiac & vascular cells 
and their native cells176, as well as any potential impacts they may exert; finally, 
clonal drift is another inescapable event that has the potential of severely 
impacting the overall reproducibility of organotypic cultures (termed ‘organoid 
heterogeneity’). To emphasize, there is still a great deal of knowledge required 
to perpetuate advancements and refinements of vascular organoid 
technologies.  
The use of animal products, such as serum or tissue scaffolds with animal 
origins, is still an existing flaw in most current setups of organotypic cultures, 
including the protocol reported by Wimmer et al, which also used Collagen I-
Matrigel and FBS to encourage formation of microvascular networks and to 
improve survivability. Inclusion of animal products can potentially lead to 
abnormal growth, premature differentiation or impeded formation of 
microvasculatures, due to batch-to-batch variations of animal products, which 
ultimately manifest as discrepancies among different studies. Such negative 
impacts may also affect drug screening results or any downstream applications. 











improvements needed to be made by using synthetic, biocompatible 
alternatives.  
Finally, undeterred by the enormous strides made in terms of translatability, 
relevancy and scalability of in vitro modelling platforms, complex in vitro 
systems would most inevitably suffer from difficulties in data integration, 
interpretation and application, not to mention the increased likelihood of 
anomalies due to the inherent unpredictability of different cell types residing in 
a constructed microenvironment. Computational modelling analysis can 
therefore be incorporated into organotypic culture setups as a mean to reliably 
extrapolate complex datasets of genomic, proteomic and metabolic information, 
and transform these datasets into mathematical models that are accurate 
representations of native biological system. Additionally, although it was 
believed that human-based modelling platforms are vastly superior in predicting 
human responses than animal-based models, implementation of computational 
models is most definitely beneficial for validating screening outcomes from 
organotypic cultures, as well as predicting relevant clinical endpoints. 
In conclusion, although current vascular organoid technologies still represents 
a primitive version of a powerful platform for studying both functional and 
genetic aspect of human vasculopathies, they have exceptional potentials in 
studying disease etiology, vascular development, high-throughput drug 
screening under simplistic set up, and providing unlimited reliable vascular 
grafts for life-threating vascular diseases. 
 
Funding  
This work was supported by British Heart Foundation (PG/15/11/31279, 
PG/15/86/31723, and PG/16/1/31892). This work forms part of the research 
portfolio for the National Institute for Health Research Biomedical Research 


















1. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, 
Norrving B, Shiue I, Ng M, Estep K, Cercy K, Murray CJL, Forouzanfar MH. Global burden 
of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for 
the Global Burden of Disease Study 2013. Lancet Neurol 2016;15:913-924. 
2. Bonaca MP, Creager MA. Pharmacological treatment and current management of 
peripheral artery disease. Circ Res 2015;116:1579-1598. 
3. Spence JD, Dresser GK. Overcoming Challenges With Statin Therapy. J Am Heart 
Assoc 2016;5. 
4. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, 
Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. 
Circulation 1995;91:2488-2496. 
5. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: 
process, indicators, risk factors and new hopes. Int J Prev Med 2014;5:927-946. 
6. Ghallab A. In vitro test systems and their limitations. Excli j 2013;12:1024-1026. 
7. Jopling C, Sleep E, Raya M, Marti M, Raya A, Izpisua Belmonte JC. Zebrafish heart 
regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 
2010;464:606-609. 
8. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, 
Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 
1998;282:1145-1147. 
9. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. 
Cell 2007;131:861-872. 
10. Howard D, Buttery LD, Shakesheff KM, Roberts SJ. Tissue engineering: strategies, 
stem cells and scaffolds. J Anat 2008;213:66-72. 
11. Bertucci TB, Dai G. Biomaterial Engineering for Controlling Pluripotent Stem Cell 
Fate. Stem Cells Int 2018;2018:9068203. 
12. Jana S, Cooper A, Zhang M. Chitosan scaffolds with unidirectional microtubular 
pores for large skeletal myotube generation. Adv Healthc Mater 2013;2:557-561. 
13. Wang S, Mo XM, Jiang BJ, Gao CJ, Wang HS, Zhuang YG, Qiu LJ. Fabrication of small-
diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to 











14. Smeriglio P, Lai JH, Yang F, Bhutani N. 3D Hydrogel Scaffolds for Articular 
Chondrocyte Culture and Cartilage Generation. J Vis Exp 2015. 
15. Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA, Massa S, Riahi R, 
Chae S, Hu N, Avci H, Zhang W, Silvestri A, Sanati Nezhad A, Manbohi A, De Ferrari F, 
Polini A, Calzone G, Shaikh N, Alerasool P, Budina E, Kang J, Bhise N, Ribas J, Pourmand 
A, Skardal A, Shupe T, Bishop CE, Dokmeci MR, Atala A, Khademhosseini A. 
Multisensor-integrated organs-on-chips platform for automated and continual in situ 
monitoring of organoid behaviors. Proc Natl Acad Sci U S A 2017;114:E2293-e2302. 
16. Badylak SF, Taylor D, Uygun K. Whole-organ tissue engineering: decellularization 
and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng 
2011;13:27-53. 
17. Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, 
Folkman J, Gimbrone MA, Jr., Anderson DJ. Expression of ephrinB2 identifies a stable 
genetic difference between arterial and venous vascular smooth muscle as well as 
endothelial cells, and marks subsets of microvessels at sites of adult 
neovascularization. Dev Biol 2001;230:139-150. 
18. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction 
between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. 
Cell 1998;93:741-753. 
19. Jones EA. The initiation of blood flow and flow induced events in early vascular 
development. Semin Cell Dev Biol 2011;22:1028-1035. 
20. Niklason L, Dai G. Arterial Venous Differentiation for Vascular Bioengineering. 
Annu Rev Biomed Eng 2018;20:431-447. 
21. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. In vitro differentiation of 
transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 
2001;19:1129-1133. 
22. Srinivasan A, Toh YC. Human Pluripotent Stem Cell-Derived Neural Crest Cells for 
Tissue Regeneration and Disease Modeling. Front Mol Neurosci 2019;12:39. 
23. Li X, Xu R, Tu X, Janairo RRR, Kwong G, Wang D, Zhu Y, Li S. Differentiation of Neural 
Crest Stem Cells in Response to Matrix Stiffness and TGF-beta1 in Vascular 
Regeneration. Stem Cells Dev 2020;29:249-256. 
24. Patsch C, Challet-Meylan L, Thoma EC, Urich E, Heckel T, O'Sullivan JF, Grainger SJ, 
Kapp FG, Sun L, Christensen K, Xia Y, Florido MH, He W, Pan W, Prummer M, Warren 
CR, Jakob-Roetne R, Certa U, Jagasia R, Freskgard PO, Adatto I, Kling D, Huang P, Zon LI, 











endothelial and smooth muscle cells from human pluripotent stem cells. Nature cell 
biology 2015;17:994-1003. 
25. Orlova VV, Drabsch Y, Freund C, Petrus-Reurer S, van den Hil FE, Muenthaisong S, 
Dijke PT, Mummery CL. Functionality of endothelial cells and pericytes from human 
pluripotent stem cells demonstrated in cultured vascular plexus and zebrafish 
xenografts. Arterioscler Thromb Vasc Biol 2014;34:177-186. 
26. Huang Y, Chen X, Che J, Zhan Q, Ji J, Fan Y. Shear Stress Promotes Arterial 
Endothelium-Oriented Differentiation of Mouse-Induced Pluripotent Stem Cells. Stem 
Cells Int 2019;2019:1847098. 
27. Ohtani-Kaneko R, Sato K, Tsutiya A, Nakagawa Y, Hashizume K, Tazawa H. 
Characterisation of human induced pluripotent stem cell-derived endothelial cells 
under shear stress using an easy-to-use microfluidic cell culture system. Biomed 
Microdevices 2017;19:91. 
28. Kane NM, Meloni M, Spencer HL, Craig MA, Strehl R, Milligan G, Houslay MD, 
Mountford JC, Emanueli C, Baker AH. Derivation of endothelial cells from human 
embryonic stem cells by directed differentiation: analysis of microRNA and 
angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010;30:1389-1397. 
29. Xiao Q, Pepe AE, Wang G, Luo Z, Zhang L, Zeng L, Zhang Z, Hu Y, Ye S, Xu Q. Nrf3-
Pla2g7 interaction plays an essential role in smooth muscle differentiation from stem 
cells. Arteriosclerosis, thrombosis, and vascular biology 2012;32:730-744. 
30. Pepe AE, Xiao Q, Zampetaki A, Zhang Z, Kobayashi A, Hu Y, Xu Q. Crucial role of 
nrf3 in smooth muscle cell differentiation from stem cells. Circulation research 
2010;106:870-879. 
31. Xiao Q, Luo Z, Pepe AE, Margariti A, Zeng L, Xu Q. Embryonic stem cell 
differentiation into smooth muscle cells is mediated by Nox4-produced H2O2. 
American journal of physiology Cell physiology 2009;296:C711-723. 
32. Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, Zhang Q, Ye J, Yan Z, 
Denduluri S, Idowu O, Li M, Shen C, Hu A, Haydon RC, Kang R, Mok J, Lee MJ, Luu HL, 
Shi LL. Bone Morphogenetic Protein (BMP) signaling in development and human 
diseases. Genes Dis 2014;1:87-105. 
33. Rahman MS, Akhtar N, Jamil HM, Banik RS, Asaduzzaman SM. TGF-beta/BMP 
signaling and other molecular events: regulation of osteoblastogenesis and bone 
formation. Bone Res 2015;3:15005. 
34. Zhang L, Jin M, Margariti A, Wang G, Luo Z, Zampetaki A, Zeng L, Ye S, Zhu J, Xiao 











BB-induced smooth muscle cell differentiation from stem cells. The Journal of 
biological chemistry 2010;285:38463-38472. 
35. Margariti A, Xiao Q, Zampetaki A, Zhang Z, Li H, Martin D, Hu Y, Zeng L, Xu Q. 
Splicing of HDAC7 modulates the SRF-myocardin complex during stem-cell 
differentiation towards smooth muscle cells. Journal of cell science 2009;122:460-470. 
36. Zeng L, Xiao Q, Margariti A, Zhang Z, Zampetaki A, Patel S, Capogrossi MC, Hu Y, 
Xu Q. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward 
endothelial cells. The Journal of cell biology 2006;174:1059-1069. 
37. Xiao Q, Zeng L, Zhang Z, Margariti A, Ali ZA, Channon KM, Xu Q, Hu Y. Sca-1+ 
progenitors derived from embryonic stem cells differentiate into endothelial cells 
capable of vascular repair after arterial injury. Arteriosclerosis, thrombosis, and 
vascular biology 2006;26:2244-2251. 
38. Zhao H, Wen G, Huang Y, Yu X, Chen Q, Afzal TA, Luong le A, Zhu J, Ye S, Zhang L, 
Xiao Q. MicroRNA-22 regulates smooth muscle cell differentiation from stem cells by 
targeting methyl CpG-binding protein 2. Arteriosclerosis, thrombosis, and vascular 
biology 2015;35:918-929. 
39. Luo Z, Wen G, Wang G, Pu X, Ye S, Xu Q, Wang W, Xiao Q. MicroRNA-200C and -
150 play an important role in endothelial cell differentiation and vasculogenesis by 
targeting transcription repressor ZEB1. Stem cells 2013;31:1749-1762. 
40. Yu X, Zhang L, Wen G, Zhao H, Luong LA, Chen Q, Huang Y, Zhu J, Ye S, Xu Q, Wang 
W, Xiao Q. Upregulated sirtuin 1 by miRNA-34a is required for smooth muscle cell 
differentiation from pluripotent stem cells. Cell death and differentiation 
2015;22:1170-1180. 
41. Yang F, Chen Q, Yang M, Maguire EM, Yu X, He S, Xiao R, Wang CS, An W, Wu W, 
Zhou Y, Xiao Q, Zhang L. Macrophage-derived MMP-8 determines smooth muscle cell 
differentiation from adventitia stem/progenitor cells and promotes neointima 
hyperplasia. Cardiovascular research 2020;116:211-225. 
42. Fang C, Wen G, Zhang L, Lin L, Moore A, Wu S, Ye S, Xiao Q. An important role of 
matrix metalloproteinase-8 in angiogenesis in vitro and in vivo. Cardiovascular 
research 2013;99:146-155. 
43. Xiao Q, Zhang F, Lin L, Fang C, Wen G, Tsai TN, Pu X, Sims D, Zhang Z, Yin X, 
Thomaszewski B, Schmidt B, Mayr M, Suzuki K, Xu Q, Ye S. Functional role of matrix 
metalloproteinase-8 in stem/progenitor cell migration and their recruitment into 
atherosclerotic lesions. Circulation research 2013;112:35-47. 











differentiate into smooth muscle cells, which is mediated by collagen IV-integrin 
alpha1/beta1/alphav and PDGF receptor pathways. American journal of physiology 
Cell physiology 2007;292:C342-352. 
45. Shi N, Chen SY. Smooth Muscle Cell Differentiation: Model Systems, Regulatory 
Mechanisms, and Vascular Diseases. J Cell Physiol 2016;231:777-787. 
46. Mack CP. Signaling mechanisms that regulate smooth muscle cell differentiation. 
Arteriosclerosis, thrombosis, and vascular biology 2011;31:1495-1505. 
47. Xie C, Ritchie RP, Huang H, Zhang J, Chen YE. Smooth muscle cell differentiation in 
vitro: models and underlying molecular mechanisms. Arterioscler Thromb Vasc Biol 
2011;31:1485-1494. 
48. Maguire EM, Xiao Q, Xu Q. Differentiation and Application of Induced Pluripotent 
Stem Cell-Derived Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol 
2017;37:2026-2037. 
49. Luo Z, Wang G, Wang W, Xiao Q, Xu Q. Signalling pathways that regulate 
endothelial differentiation from stem cells. Front Biosci (Landmark Ed) 2011;16:472-
485. 
50. Maguire EM, Xiao Q. Noncoding RNAs in vascular smooth muscle cell function and 
neointimal hyperplasia. The FEBS journal 2020. 
51. Zhou Y, Yan H, Guo M, Zhu J, Xiao Q, Zhang L. Reactive oxygen species in vascular 
formation and development. Oxid Med Cell Longev 2013;2013:374963. 
52. Kane NM, Xiao Q, Baker AH, Luo Z, Xu Q, Emanueli C. Pluripotent stem cell 
differentiation into vascular cells: a novel technology with promises for vascular 
re(generation). Pharmacology & therapeutics 2011;129:29-49. 
53. Xiao Q, Wang G, Luo Z, Xu Q. The mechanism of stem cell differentiation into 
smooth muscle cells. Thrombosis and haemostasis 2010;104:440-448. 
54. Siebel C, Lendahl U. Notch Signaling in Development, Tissue Homeostasis, and 
Disease. Physiol Rev 2017;97:1235-1294. 
55. Henshall TL, Keller A, He L, Johansson BR, Wallgard E, Raschperger E, Mae MA, Jin 
S, Betsholtz C, Lendahl U. Notch3 is necessary for blood vessel integrity in the central 
nervous system. Arterioscler Thromb Vasc Biol 2015;35:409-420. 
56. Volz KS, Jacobs AH, Chen HI, Poduri A, McKay AS, Riordan DP, Kofler N, Kitajewski 
J, Weissman I, Red-Horse K. Pericytes are progenitors for coronary artery smooth 











57. Wang Q, Zhao N, Kennard S, Lilly B. Notch2 and Notch3 function together to 
regulate vascular smooth muscle development. PLoS One 2012;7:e37365. 
58. Wang Y, Pan L, Moens CB, Appel B. Notch3 establishes brain vascular integrity by 
regulating pericyte number. Development 2014;141:307-317. 
59. Ando K, Wang W, Peng D, Chiba A, Lagendijk AK, Barske L, Crump JG, Stainier DYR, 
Lendahl U, Koltowska K, Hogan BM, Fukuhara S, Mochizuki N, Betsholtz C. Peri-arterial 
specification of vascular mural cells from naive mesenchyme requires Notch signaling. 
Development 2019;146. 
60. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH. The 
notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 
2009;137:1124-1135. 
61. Cappellari O, Benedetti S, Innocenzi A, Tedesco FS, Moreno-Fortuny A, Ugarte G, 
Lampugnani MG, Messina G, Cossu G. Dll4 and PDGF-BB convert committed skeletal 
myoblasts to pericytes without erasing their myogenic memory. Dev Cell 2013;24:586-
599. 
62. Ong CT, Cheng HT, Chang LW, Ohtsuka T, Kageyama R, Stormo GD, Kopan R. Target 
selectivity of vertebrate notch proteins. Collaboration between discrete domains and 
CSL-binding site architecture determines activation probability. The Journal of 
biological chemistry 2006;281:5106-5119. 
63. Li Y, Takeshita K, Liu PY, Satoh M, Oyama N, Mukai Y, Chin MT, Krebs L, Kotlikoff MI, 
Radtke F, Gridley T, Liao JK. Smooth muscle Notch1 mediates neointimal formation 
after vascular injury. Circulation 2009;119:2686-2692. 
64. Zhang C, Chen D, Maguire EM, He S, Chen J, An W, Yang M, Afzal TA, Luong LA, 
Zhang L, Lei H, Wu Q, Xiao Q. Cbx3 inhibits vascular smooth muscle cell proliferation, 
migration, and neointima formation. Cardiovascular research 2018;114:443-455. 
65. Chen Q, Yang F, Guo M, Wen G, Zhang C, Luong le A, Zhu J, Xiao Q, Zhang L. miRNA-
34a reduces neointima formation through inhibiting smooth muscle cell proliferation 
and migration. Journal of molecular and cellular cardiology 2015;89:75-86. 
66. Burgy O, Königshoff M. The WNT signaling pathways in wound healing and fibrosis. 
Matrix Biol 2018;68-69:67-80. 
67. Meyer IS, Leuschner F. The role of Wnt signaling in the healing myocardium: a 
focus on cell specificity. Basic Res Cardiol 2018;113:44. 
68. Tam PP, Loebel DA. Gene function in mouse embryogenesis: get set for 











69. Kimelman D. Mesoderm induction: from caps to chips. Nat Rev Genet 2006;7:360-
372. 
70. Hübner K, Grassme KS, Rao J, Wenke NK, Zimmer CL, Korte L, Müller K, Sumanas 
S, Greber B, Herzog W. Wnt signaling positively regulates endothelial cell fate 
specification in the Fli1a-positive progenitor population via Lef1. Dev Biol 
2017;430:142-155. 
71. Lawson ND, Vogel AM, Weinstein BM. sonic hedgehog and vascular endothelial 
growth factor act upstream of the Notch pathway during arterial endothelial 
differentiation. Dev Cell 2002;3:127-136. 
72. Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, Campos-Ortega JA, Weinstein 
BM. Notch signaling is required for arterial-venous differentiation during embryonic 
vascular development. Development 2001;128:3675-3683. 
73. Kume T. Specification of arterial, venous, and lymphatic endothelial cells during 
embryonic development. Histol Histopathol 2010;25:637-646. 
74. Lawson ND, Weinstein BM. Arteries and veins: making a difference with zebrafish. 
Nat Rev Genet 2002;3:674-682. 
75. Weinstein BM, Lawson ND. Arteries, veins, Notch, and VEGF. Cold Spring Harb 
Symp Quant Biol 2002;67:155-162. 
76. Wang X, Hu G, Gao X, Wang Y, Zhang W, Harmon EY, Zhi X, Xu Z, Lennartz MR, 
Barroso M, Trebak M, Chen C, Zhou J. The induction of yes-associated protein 
expression after arterial injury is crucial for smooth muscle phenotypic modulation 
and neointima formation. Arterioscler Thromb Vasc Biol 2012;32:2662-2669. 
77. Cho H, Kim J, Ahn JH, Hong YK, Makinen T, Lim DS, Koh GY. YAP and TAZ Negatively 
Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis. Circulation 
research 2019;124:225-242. 
78. Grimm L, Nakajima H, Chaudhury S, Bower NI, Okuda KS, Cox AG, Harvey NL, 
Koltowska K, Mochizuki N, Hogan BM. Yap1 promotes sprouting and proliferation of 
lymphatic progenitors downstream of Vegfc in the zebrafish trunk. eLife 2019;8. 
79. Wang X, Freire Valls A, Schermann G, Shen Y, Moya IM, Castro L, Urban S, Solecki 
GM, Winkler F, Riedemann L, Jain RK, Mazzone M, Schmidt T, Fischer T, Halder G, Ruiz 
de Almodovar C. YAP/TAZ Orchestrate VEGF Signaling during Developmental 
Angiogenesis. Developmental cell 2017;42:462-478 e467. 
80. Manderfield LJ, Aghajanian H, Engleka KA, Lim LY, Liu F, Jain R, Li L, Olson EN, 











differentiation of neural crest. Development 2015;142:2962-2971. 
81. Singh A, Ramesh S, Cibi DM, Yun LS, Li J, Li L, Manderfield LJ, Olson EN, Epstein JA, 
Singh MK. Hippo Signaling Mediators Yap and Taz Are Required in the Epicardium for 
Coronary Vasculature Development. Cell reports 2016;15:1384-1393. 
82. Andersen P, Uosaki H, Shenje LT, Kwon C. Non-canonical Notch signaling: emerging 
role and mechanism. Trends Cell Biol 2012;22:257-265. 
83. Ayaz F, Osborne BA. Non-canonical notch signaling in cancer and immunity. Front 
Oncol 2014;4:345. 
84. Martinez Arias A, Zecchini V, Brennan K. CSL-independent Notch signalling: a 
checkpoint in cell fate decisions during development? Current opinion in genetics & 
development 2002;12:524-533. 
85. Sanalkumar R, Dhanesh SB, James J. Non-canonical activation of Notch 
signaling/target genes in vertebrates. Cellular and molecular life sciences : CMLS 
2010;67:2957-2968. 
86. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, Srivastava D. Notch post-
translationally regulates beta-catenin protein in stem and progenitor cells. Nature cell 
biology 2011;13:1244-1251. 
87. Liu Z, Sneve M, Haroldson TA, Smith JP, Drewes LR. Regulation of Monocarboxylic 
Acid Transporter 1 Trafficking by the Canonical Wnt/β-Catenin Pathway in Rat Brain 
Endothelial Cells Requires Cross-talk with Notch Signaling. J Biol Chem 2016;291:8059-
8069. 
88. Conte MS. Critical appraisal of surgical revascularization for critical limb ischemia. 
J Vasc Surg 2013;57:8s-13s. 
89. Pashneh-Tala S, MacNeil S, Claeyssens F. The Tissue-Engineered Vascular Graft-
Past, Present, and Future. Tissue Eng Part B Rev 2016;22:68-100. 
90. Matsuzaki Y, John K, Shoji T, Shinoka T. The Evolution of Tissue Engineered Vascular 
Graft Technologies: From Preclinical Trials to Advancing Patient Care. Appl Sci (Basel) 
2019;9. 
91. Manikowski D, Andrée B, Samper E, Saint-Marc C, Olmer R, Vogt P, Strauß S, 
Haverich A, Hilfiker A. Human adipose tissue-derived stromal cells in combination with 
exogenous stimuli facilitate three-dimensional network formation of human 
endothelial cells derived from various sources. Vascul Pharmacol 2018;106:28-36. 











Halvorsen Y, Ting JP, Storms RW, Goh B, Kilroy G, Wu X, Gimble JM. The immunogenicity 
of human adipose-derived cells: temporal changes in vitro. Stem Cells 2006;24:1246-
1253. 
93. Collado MS, Cole BK, Figler RA, Lawson M, Manka D, Simmers MB, Hoang S, 
Serrano F, Blackman BR, Sinha S, Wamhoff BR. Exposure of Induced Pluripotent Stem 
Cell-Derived Vascular Endothelial and Smooth Muscle Cells in Coculture to 
Hemodynamics Induces Primary Vascular Cell-Like Phenotypes. Stem Cells Transl Med 
2017;6:1673-1683. 
94. Luo J, Qin L, Zhao L, Gui L, Ellis MW, Huang Y, Kural MH, Clark JA, Ono S, Wang J, 
Yuan Y, Zhang SM, Cong X, Li G, Riaz M, Lopez C, Hotta A, Campbell S, Tellides G, Dardik 
A, Niklason LE, Qyang Y. Tissue-Engineered Vascular Grafts with Advanced Mechanical 
Strength from Human iPSCs. Cell Stem Cell 2020;26:251-261.e258. 
95. Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for 
maternal and offspring's health. Nature medicine 2013;19:548-556. 
96. Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia 
JV, Reichenspurner H, Davis MM, Lanier LL, Schrepfer S. Hypoimmunogenic derivatives 
of induced pluripotent stem cells evade immune rejection in fully immunocompetent 
allogeneic recipients. Nat Biotechnol 2019;37:252-258. 
97. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van 
Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells 
and leukemia cells to avoid phagocytosis. Cell 2009;138:271-285. 
98. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is 
sufficient for the inducible expression of major histocompatibility complex class II 
genes. J Exp Med 1994;180:1367-1374. 
99. Rossant J. Gene editing in human development: ethical concerns and practical 
applications. Development 2018;145. 
100. Peris-Torres C, Serrano O, Plaza-Calonge MDC, Rodriguez-Manzaneque JC. 
Inhibition of ADAMTS1 Expression by Lentiviral CRISPR/Cas9 Gene Editing Technology. 
Methods Mol Biol 2020;2043:13-24. 
101. Doetschman T, Georgieva T. Gene Editing With CRISPR/Cas9 RNA-Directed 
Nuclease. Circ Res 2017;120:876-894. 
102. Crist AM, Young C, Meadows SM. Characterization of arteriovenous identity 
in the developing neonate mouse retina. Gene Expr Patterns 2017;23-24:22-31. 











development and disease. Nat Cell Biol 2016;18:246-254. 
104. Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ. Prostate epithelial 
cell lines form spheroids with evidence of glandular differentiation in three-
dimensional Matrigel cultures. Br J Cancer 2001;85:590-599. 
105. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, Ellis E, 
van Wenum M, Fuchs SA, de Ligt J, van de Wetering M, Sasaki N, Boers SJ, Kemperman 
H, de Jonge J, Ijzermans JN, Nieuwenhuis EE, Hoekstra R, Strom S, Vries RR, van der 
Laan LJ, Cuppen E, Clevers H. Long-term culture of genome-stable bipotent stem cells 
from adult human liver. Cell 2015;160:299-312. 
106. Wang S, Wang X, Tan Z, Su Y, Liu J, Chang M, Yan F, Chen J, Chen T, Li C, Hu J, 
Wang Y. Human ESC-derived expandable hepatic organoids enable therapeutic liver 
repopulation and pathophysiological modeling of alcoholic liver injury. Cell Res 
2019;29:1009-1026. 
107. Dye BR, Hill DR, Ferguson MA, Tsai YH, Nagy MS, Dyal R, Wells JM, Mayhew 
CN, Nattiv R, Klein OD, White ES, Deutsch GH, Spence JR. In vitro generation of human 
pluripotent stem cell derived lung organoids. Elife 2015;4. 
108. Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, Clevers H. 
Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc 
2016;11:347-358. 
109. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, 
Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-
Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali 
M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, 
Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, 
Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N. Patient-derived 
organoids model treatment response of metastatic gastrointestinal cancers. Science 
2018;359:920-926. 
110. McCracken KW, Cata EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich 
BE, Tsai YH, Mayhew CN, Spence JR, Zavros Y, Wells JM. Modelling human development 
and disease in pluripotent stem-cell-derived gastric organoids. Nature 2014;516:400-
404. 
111. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, 
Homfray T, Penninger JM, Jackson AP, Knoblich JA. Cerebral organoids model human 
brain development and microcephaly. Nature 2013;501:373-379. 











Depletes Neural Progenitors in Human Cerebral Organoids through Activation of the 
Innate Immune Receptor TLR3. Cell Stem Cell 2016;19:258-265. 
113. Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, 
Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de 
Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, 
Beekman JM. Characterizing responses to CFTR-modulating drugs using rectal 
organoids derived from subjects with cystic fibrosis. Sci Transl Med 2016;8:344ra384. 
114. Vives J, Batlle-Morera L. The challenge of developing human 3D organoids into 
medicines.  Stem Cell Res Ther, 2020:72. 
115. Yui S, Nakamura T, Sato T, Nemoto Y, Mizutani T, Zheng X, Ichinose S, Nagaishi 
T, Okamoto R, Tsuchiya K, Clevers H, Watanabe M. Functional engraftment of colon 
epithelium expanded in vitro from a single adult Lgr5(+) stem cell. Nat Med 
2012;18:618-623. 
116. Daviaud N, Friedel RH, Zou H. Vascularization and Engraftment of 
Transplanted Human Cerebral Organoids in Mouse Cortex. eNeuro 2018;5. 
117. Hu H, Gehart H, Artegiani B, C LO-I, Dekkers F, Basak O, van Es J, Chuva de 
Sousa Lopes SM, Begthel H, Korving J, van den Born M, Zou C, Quirk C, Chiriboga L, 
Rice CM, Ma S, Rios A, Peters PJ, de Jong YP, Clevers H. Long-Term Expansion of 
Functional Mouse and Human Hepatocytes as 3D Organoids. Cell 2018;175:1591-
1606.e1519. 
118. Goldie LC, Nix MK, Hirschi KK. Embryonic vasculogenesis and hematopoietic 
specification. Organogenesis 2008;4:257-263. 
119. Finnemore A, Groves A. Physiology of the fetal and transitional circulation. 
Semin Fetal Neonatal Med 2015;20:210-216. 
120. Adams RH, Alitalo K. Molecular regulation of angiogenesis and 
lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8:464-478. 
121. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 
2000;6:389-395. 
122. Song HG, Rumma RT, Ozaki CK, Edelman ER, Chen CS. Vascular Tissue 
Engineering: Progress, Challenges, and Clinical Promise. Cell Stem Cell 2018;22:340-
354. 
123. Wimmer RA, Leopoldi A, Aichinger M, Kerjaschki D, Penninger JM. Generation 












124. Huch M, Knoblich JA, Lutolf MP, Martinez-Arias A. The hope and the hype of 
organoid research. Development 2017;144:938-941. 
125. Phipson B, Er PX, Combes AN, Forbes TA, Howden SE, Zappia L, Yen HJ, Lawlor 
KT, Hale LJ, Sun J, Wolvetang E, Takasato M, Oshlack A, Little MH. Evaluation of 
variability in human kidney organoids. Nat Methods 2019;16:79-87. 
126. Damani SB, Topol EJ. Emerging genomic applications in coronary artery 
disease. JACC Cardiovasc Interv 2011;4:473-482. 
127. Grebenyuk S, Ranga A. Engineering Organoid Vascularization. Front Bioeng 
Biotechnol 2019;7:39. 
128. Pham MT, Pollock KM, Rose MD, Cary WA, Stewart HR, Zhou P, Nolta JA, 
Waldau B. Generation of human vascularized brain organoids. Neuroreport 
2018;29:588-593. 
129. Lancaster MA, Knoblich JA. Generation of cerebral organoids from human 
pluripotent stem cells. Nat Protoc 2014;9:2329-2340. 
130. Mansour AA, Goncalves JT, Bloyd CW, Li H, Fernandes S, Quang D, Johnston S, 
Parylak SL, Jin X, Gage FH. An in vivo model of functional and vascularized human brain 
organoids. Nat Biotechnol 2018;36:432-441. 
131. Wörsdörfer P, Dalda N, Kern A, Krüger S, Wagner N, Kwok CK, Henke E, Ergün 
S. Generation of complex human organoid models including vascular networks by 
incorporation of mesodermal progenitor cells. Sci Rep 2019;9:15663. 
132. Straub AC, Zeigler AC, Isakson BE. The myoendothelial junction: connections 
that deliver the message. Physiology (Bethesda) 2014;29:242-249. 
133. Lee S, Kim JE, Johnson BA, Andukuri A, Yoon YS. Direct reprogramming into 
endothelial cells: a new source for vascular regeneration. Regen Med 2017;12:317-320. 
134. Cakir B, Xiang Y, Tanaka Y, Kural MH, Parent M, Kang YJ, Chapeton K, Patterson 
B, Yuan Y, He CS, Raredon MSB, Dengelegi J, Kim KY, Sun P, Zhong M, Lee S, Patra P, 
Hyder F, Niklason LE, Lee SH, Yoon YS, Park IH. Engineering of human brain organoids 
with a functional vascular-like system. Nat Methods 2019;16:1169-1175. 
135. Orsi NM, Reischl JB. Mammalian embryo co-culture: trials and tribulations of 
a misunderstood method. Theriogenology 2007;67:441-458. 
136. Ham O, Jin YB, Kim J, Lee MO. Blood vessel formation in cerebral organoids 












137. Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, Nishinakamura R. 
Redefining the in vivo origin of metanephric nephron progenitors enables generation 
of complex kidney structures from pluripotent stem cells. Cell Stem Cell 2014;14:53-
67. 
138. Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV. 
Nephron organoids derived from human pluripotent stem cells model kidney 
development and injury. Nat Biotechnol 2015;33:1193-1200. 
139. Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li 
MK, Hughes MR, Werff RV, Peters DT, Lu J, Baccei A, Siedlecki AM, Valerius MT, 
Musunuru K, McNagny KM, Steinman TI, Zhou J, Lerou PH, Bonventre JV. Modelling 
kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent 
epiblast spheroids. Nat Commun 2015;6:8715. 
140. van den Berg CW, Ritsma L, Avramut MC, Wiersma LE, van den Berg BM, 
Leuning DG, Lievers E, Koning M, Vanslambrouck JM, Koster AJ, Howden SE, Takasato 
M, Little MH, Rabelink TJ. Renal Subcapsular Transplantation of PSC-Derived Kidney 
Organoids Induces Neo-vasculogenesis and Significant Glomerular and Tubular 
Maturation In Vivo. Stem Cell Reports 2018;10:751-765. 
141. Homan KA, Gupta N, Kroll KT, Kolesky DB, Skylar-Scott M, Miyoshi T, Mau D, 
Valerius MT, Ferrante T, Bonventre JV, Lewis JA, Morizane R. Flow-enhanced 
vascularization and maturation of kidney organoids in vitro. Nat Methods 
2019;16:255-262. 
142. Morizane R, Bonventre JV. Generation of nephron progenitor cells and kidney 
organoids from human pluripotent stem cells. Nat Protoc 2017;12:195-207. 
143. Low JH, Li P, Chew EGY, Zhou B, Suzuki K, Zhang T, Lian MM, Liu M, Aizawa E, 
Rodriguez Esteban C, Yong KSM, Chen Q, Campistol JM, Fang M, Khor CC, Foo JN, 
Izpisua Belmonte JC, Xia Y. Generation of Human PSC-Derived Kidney Organoids with 
Patterned Nephron Segments and a De Novo Vascular Network. Cell Stem Cell 
2019;25:373-387.e379. 
144. Holloway EM, Capeling MM, Spence JR. Biologically inspired approaches to 
enhance human organoid complexity. Development 2019;146. 
145. Ma Z, Wang J, Loskill P, Huebsch N, Koo S, Svedlund FL, Marks NC, Hua EW, 
Grigoropoulos CP, Conklin BR, Healy KE. Self-organizing human cardiac microchambers 
mediated by geometric confinement. Nat Commun 2015;6:7413. 
146. Mills RJ, Titmarsh DM, Koenig X, Parker BL, Ryall JG, Quaife-Ryan GA, Voges 











Gregorevic P, Xin M, Thomas WG, Parton RG, Nielsen LK, Launikonis BS, James DE, 
Elliott DA, Porrello ER, Hudson JE. Functional screening in human cardiac organoids 
reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. Proc Natl Acad Sci 
U S A 2017;114:E8372-e8381. 
147. Richards DJ, Coyle RC, Tan Y, Jia J, Wong K, Toomer K, Menick DR, Mei Y. 
Inspiration from heart development: Biomimetic development of functional human 
cardiac organoids. Biomaterials 2017;142:112-123. 
148. Zhang YS, Arneri A, Bersini S, Shin SR, Zhu K, Goli-Malekabadi Z, Aleman J, 
Colosi C, Busignani F, Dell'Erba V, Bishop C, Shupe T, Demarchi D, Moretti M, Rasponi 
M, Dokmeci MR, Atala A, Khademhosseini A. Bioprinting 3D microfibrous scaffolds for 
engineering endothelialized myocardium and heart-on-a-chip. Biomaterials 
2016;110:45-59. 
149. Mills RJ, Parker BL, Quaife-Ryan GA, Voges HK, Needham EJ, Bornot A, Ding M, 
Andersson H, Polla M, Elliott DA, Drowley L, Clausen M, Plowright AT, Barrett IP, Wang 
QD, James DE, Porrello ER, Hudson JE. Drug Screening in Human PSC-Cardiac 
Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. 
Cell stem cell 2019;24:895-907 e896. 
150. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno 
Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional 
human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481-484. 
151. Pettinato G, Lehoux S, Ramanathan R, Salem MM, He LX, Muse O, 
Flaumenhaft R, Thompson MT, Rouse EA, Cummings RD, Wen X, Fisher RA. Generation 
of fully functional hepatocyte-like organoids from human induced pluripotent stem 
cells mixed with Endothelial Cells. Sci Rep 2019;9:8920. 
152. Takebe T, Sekine K, Kimura M, Yoshizawa E, Ayano S, Koido M, Funayama S, 
Nakanishi N, Hisai T, Kobayashi T, Kasai T, Kitada R, Mori A, Ayabe H, Ejiri Y, Amimoto N, 
Yamazaki Y, Ogawa S, Ishikawa M, Kiyota Y, Sato Y, Nozawa K, Okamoto S, Ueno Y, 
Taniguchi H. Massive and Reproducible Production of Liver Buds Entirely from Human 
Pluripotent Stem Cells. Cell Rep 2017;21:2661-2670. 
153. Koui Y, Kido T, Ito T, Oyama H, Chen SW, Katou Y, Shirahige K, Miyajima A. An 
In Vitro Human Liver Model by iPSC-Derived Parenchymal and Non-parenchymal Cells. 
Stem Cell Reports 2017;9:490-498. 
154. Goulart E, de Caires-Junior LC, Telles-Silva KA, Araujo BHS, Kobayashi GS, 
Musso CM, Assoni AF, Oliveira D, Caldini E, Gerstenhaber JA, Raia S, Lelkes PI, Zatz M. 
Adult and iPS-derived non-parenchymal cells regulate liver organoid development 











155. Vargas-Valderrama A, Messina A, Mitjavila-Garcia MT, Guenou H. The 
endothelium, a key actor in organ development and hPSC-derived organoid 
vascularization. J Biomed Sci 2020;27:67. 
156. Dye BR, Dedhia PH, Miller AJ, Nagy MS, White ES, Shea LD, Spence JR. A 
bioengineered niche promotes in vivo engraftment and maturation of pluripotent 
stem cell derived human lung organoids. Elife 2016;5. 
157. Takahashi Y, Takebe T, Taniguchi H. Methods for Generating Vascularized Islet-
Like Organoids Via Self-Condensation. Curr Protoc Stem Cell Biol 2018;45:e49. 
158. Candiello J, Grandhi TSP, Goh SK, Vaidya V, Lemmon-Kishi M, Eliato KR, Ros R, 
Kumta PN, Rege K, Banerjee I. 3D heterogeneous islet organoid generation from 
human embryonic stem cells using a novel engineered hydrogel platform. Biomaterials 
2018;177:27-39. 
159. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, 
Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. Directed differentiation of 
human pluripotent stem cells into intestinal tissue in vitro. Nature 2011;470:105-109. 
160. Watson CL, Mahe MM, Múnera J, Howell JC, Sundaram N, Poling HM, 
Schweitzer JI, Vallance JE, Mayhew CN, Sun Y, Grabowski G, Finkbeiner SR, Spence JR, 
Shroyer NF, Wells JM, Helmrath MA. An in vivo model of human small intestine using 
pluripotent stem cells. Nat Med 2014;20:1310-1314. 
161. Tsilibary EC. Microvascular basement membranes in diabetes mellitus. J 
Pathol 2003;200:537-546. 
162. Zheng X, Narayanan S, Sunkari VG, Eliasson S, Botusan IR, Grünler J, Catrina 
AI, Radtke F, Xu C, Zhao A, Ekberg NR, Lendahl U, Catrina SB. Triggering of a Dll4-Notch1 
loop impairs wound healing in diabetes. Proc Natl Acad Sci U S A 2019;116:6985-6994. 
163. Liu H, Zhang W, Lilly B. Evaluation of Notch3 Deficiency in Diabetes-Induced 
Pericyte Loss in the Retina. J Vasc Res 2018;55:308-318. 
164. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of 
angiogenesis. Nature 2011;473:298-307. 
165. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660. 
166. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, Galper JB. Human 
umbilical vein endothelial cells and human dermal microvascular endothelial cells 
offer new insights into the relationship between lipid metabolism and angiogenesis. 











167. Rak-Raszewska A, Hauser PV, Vainio S. Organ In Vitro Culture: What Have We 
Learned about Early Kidney Development? Stem Cells Int 2015;2015:959807. 
168. Campisi M, Shin Y, Osaki T, Hajal C, Chiono V, Kamm RD. 3D self-organized 
microvascular model of the human blood-brain barrier with endothelial cells, pericytes 
and astrocytes. Biomaterials 2018;180:117-129. 
169. Menon NV, Tay HM, Wee SN, Li KHH, Hou HW. Micro-engineered perfusable 
3D vasculatures for cardiovascular diseases. Lab Chip 2017;17:2960-2968. 
170. Lin NYC, Homan KA, Robinson SS, Kolesky DB, Duarte N, Moisan A, Lewis JA. 
Renal reabsorption in 3D vascularized proximal tubule models. Proc Natl Acad Sci U S 
A 2019;116:5399-5404. 
171. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. 
Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580. 
172. Cyron CJ, Humphrey JD. Vascular homeostasis and the concept of 
mechanobiological stability. Int J Eng Sci 2014;85:203-223. 
173. Noonan J, Grassia G, MacRitchie N, Garside P, Guzik TJ, Bradshaw AC, Maffia 
P. A Novel Triple-Cell Two-Dimensional Model to Study Immune-Vascular Interplay in 
Atherosclerosis. Front Immunol 2019;10:849. 
174. Pettinato G, Wen X, Zhang N. Formation of well-defined embryoid bodies 
from dissociated human induced pluripotent stem cells using microfabricated cell-
repellent microwell arrays. Sci Rep 2014;4:7402. 
175. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran 
A, Wang L, Arora K, Rosenthal NA, Tallquist MD. Revisiting Cardiac Cellular Composition. 
Circ Res 2016;118:400-409. 
176. Devalla HD, Passier R. Cardiac differentiation of pluripotent stem cells and 
implications for modeling the heart in health and disease. Sci Transl Med 2018;10. 
177. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the 
activation mechanism. Cell 2009;137:216-233. 
178. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, Hatakeyama S, 
Bessho Y, Kageyama R, Suda T, Nakayama KI. Mouse Fbw7/Sel-10/Cdc4 is required for 
notch degradation during vascular development. J Biol Chem 2004;279:9417-9423. 
179. Daud M, Rana MA, Husnain T, Ijaz B. Modulation of Wnt signaling pathway by 











180. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 
2008;4:68-75. 
181. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude 
for more. Circulation research 2010;106:1798-1806. 
182. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER. 
Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor 
pathway regulating Wnt signaling. J Biol Chem 2002;277:21657-21665. 
183. Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, Kühl M, 
Wedlich D, Birchmeier W. Functional interaction of an axin homolog, conductin, with 
beta-catenin, APC, and GSK3beta. Science 1998;280:596-599. 
184. Kim KA, Zhao J, Andarmani S, Kakitani M, Oshima T, Binnerts ME, Abo A, 
Tomizuka K, Funk WD. R-Spondin proteins: a novel link to beta-catenin activation. Cell 
cycle 2006;5:23-26. 
185. Mueller TD, Nickel J. Promiscuity and specificity in BMP receptor activation. 
FEBS Lett 2012;586:1846-1859. 
186. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane 
to nucleus through SMAD proteins. Nature 1997;390:465-471. 
187. Huang Z, Wang D, Ihida-Stansbury K, Jones PL, Martin JF. Defective pulmonary 
vascular remodeling in Smad8 mutant mice. Hum Mol Genet 2009;18:2791-2801. 
188. Chan MC, Hilyard AC, Wu C, Davis BN, Hill NS, Lal A, Lieberman J, Lagna G, 
Hata A. Molecular basis for antagonism between PDGF and the TGFbeta family of 
signalling pathways by control of miR-24 expression. Embo j 2010;29:559-573. 
189. Bai H, Gao Y, Arzigian M, Wojchowski DM, Wu WS, Wang ZZ. BMP4 regulates 
vascular progenitor development in human embryonic stem cells through a Smad-
dependent pathway. J Cell Biochem 2010;109:363-374. 
190. DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, Palisi TM, 
Sullivan KA, Thomas KA. Purification and characterization of a naturally occurring 
vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem 
1995;270:7717-7723. 
191. Pagès G, Pouysségur J. Transcriptional regulation of the Vascular Endothelial 
Growth Factor gene--a concert of activating factors. Cardiovasc Res 2005;65:564-573. 
192. Kappert K, Peters KG, Böhmer FD, Ostman A. Tyrosine phosphatases in vessel 











193. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-
regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 
1999;41:773-780. 
194. Nourse MB, Halpin DE, Scatena M, Mortisen DJ, Tulloch NL, Hauch KD, Torok-
Storb B, Ratner BD, Pabon L, Murry CE. VEGF induces differentiation of functional 
endothelium from human embryonic stem cells: implications for tissue engineering. 
Arterioscler Thromb Vasc Biol 2010;30:80-89. 
195. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in 
physiology and medicine. Genes Dev 2008;22:1276-1312. 
196. Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B 
and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during 
embryonic blood vessel formation in the mouse. Development 1999;126:3047-3055. 
197. Chaudhary LR, Hruska KA. The cell survival signal Akt is differentially activated 
by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem 2001;81:304-311. 
198. Ball SG, Shuttleworth CA, Kielty CM. Mesenchymal stem cells and 





















regulators & Key 
response element 






Dll 1, 3 and 4; 













RTGRGAR (where R 
is G or A) 
 
Ligand-receptor type-
dependent effect and 
region-specific 
distinctions; 
Notch3 and Notch2 
predominately regulate 
MC development, while 
Notch1 and Notch4 








Wnt-1, -2, -3, 
























Ligand- and/or cellular 
context-dependent 
manner: 
Maintains stem cell 
function & tissue 
homeostasis cell; 
Controlling cell fate 






network formation and 











Smad-1, -5, -8 





































mediator Smd-4 and 
form a signalling 
complex, which is 
translocated into the 





binding element motif 
































is triggered by VEGF 
ligand binding, then 
initiate downstream 
cascade via protein 
kinase mediators  





Critical regulator of 
angiogenesis in both 
adult and foetal 
development; 
Promotes endothelial 
stem cell differentiation 
and induce 

























PDGF ligand dimers (-
AA, -BB, AB) exhibits 












specification of MSCs 
into mesenchymal 
lineages; 
Directs differentiation of 












Table 1. Brief summarization of Notch, Wnt, BMP, VEGF and PDGF signalling pathways 
and their underlying roles in vascular cell specification and development. Abbreviation: 
Dll, Delta-like; NICD, Notch intracellular domain; Lrp, lipoprotein receptor-related protein; RBPJ, 
recombination signal sequence-binding protein Jkappa; MAML, Mastermind-like coactivator; 
TCF/LEF, T-cell factor/lymphoid enhancer factor; MC, mural cell; EC, endothelial cell; MSC, 
mesenchymal stem cell; VSMC, vascular smooth muscle cells; BMP, bone morphogenetic 
protein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor 
receptor; PIGF, placental growth factor; PI3K, phosphotidylinositol-3 kinase; MAPK, mitogen-
activated protein kinase; PLCγ, phospholipase C gamma; PKC, protein kinase C; PDGF, 















based therapies  
Challenges/Concerns Further measurements 
PSC clonal variation Huge variabilities were reported in 
different PSC-derived organoids 
due to the variations existed in the 
different PSC lines including 
epigenetic profiles, gene/marker 
expressions, as well as 
unpredictable long-term genomic 
destabilities 
To generate more PSC lines 
from a diverse pool of 
genetic/epigenetic 
backgrounds, and conduct 
long-term in vitro and in vivo 
rigorous functional 
characterisation of PSC lines 
and PSC-derived organoids. 
Widely accepted 
international guideline and 
standardised (well-
characterised) protocols are 
urgently required to 
circumvent this issue    
Size and architectural 
differences 
Organoids are usually much 
smaller in size comparing to in vivo 
organs, mainly due to the 
constraint of culture conditions and 
lack of vascularization 
Further optimization into the 
culture conditions using 
novel culture technologies 
(e.g., spinning 
bioreactors and orbital 
shakers) that could 
improve oxygenation and 
increase nutrient availability 




Reproducibility Batch-to-batch variations that may 
negatively affect treatment 
outcomes and raise safety 
concerns 
To develop experimental 
model systems with high 
fidelity, robustness of cell 
fate specification, and 
precision of self-assembly 
into higher-order organoids  
Scalability Large-scale production of 
functional organoids are still 
unachievable in current laboratory 
settings 
Utilisation of GMP-qualified 
PSC lines and products, 
standardised and scalable 
protocols, as well as step-














Lack of cell-type diversity and 
communication leads to 
inadequate functional development 




hypoxia, nutrients, PH, 
electrolyte, etc) could be 
incorporated into the 
experimental 
model systems to produce 
functional and dynamic 
organoids 
Lack of pre-clinical 
validation 
Currently, organoid-based pre-
clinical studies are largely 
conducted on small animals 
Examine the in vivo long-
term patency, compatibility, 
and applicability in large 
animals with human disease 
settings 
Limited 
understanding of cell 
types 
Cell types in organoid models 
were currently validated using 
staining for known marker genes, 
which need to be more extensively 
characterized for it to be 
determined if they are truly 
reflective of the rich cell diversity 
found in the complex human 
organs 
New technologies such as 
single-cell RNA-sequencing 
should be used to better 
define the molecular 
taxonomy of cell types within 
organoids 
Lack of stable 
organized elastin 
A lack of stable organized elastin 
in the vascular organoids is likely 
to contribute to poor in vivo 
patency and/or vascular rupture  
New approaches in 
stimulating elastogenesis in 
the vascular organoids 
should be 
developed/incorporated into 
the current protocols, such 
as promoting de novo 
generation of elastic 
fibers by SMCs, 
incorporating engineered 
synthetic elastin into 


















Current studies are mainly focused 
on gene/protein expression, and 
have limitations in capturing the 
defining features of cellular 
identity/properties within organoids 
More effective identification 
and comparisons of cellular 
composition in organoids 




of cell types in organoids 
Lack of knowledge 
into the interactions 
of organoids with 
other organs and the 
environment 
A clear drawback of current 
organoid systems is lacking of 
interorgan communication. Its 
interaction with local and remote 
environment remains elusive 
More efforts are urgently 
required to develop an 
‘organoid-on-a-chip’ 
technology 
Table 2. Potential challenges that hinder the applications of organoid in regenerative 












Figure 1. Spatial arrangement of vascular system. Endothelial cells 
constitute the inner layer of all types of blood vessels, where smooth muscle 
cells make up the middle layer (except for capillaries). Moreover, the middle 
layer of veins is thinner than that of arteries. Arterioles and venules are the 
secondary vessels of arteries and veins, respectively. As for capillaries, 
pericytes can be readily found just in-between the endothelial cells and 
basement membrane. 
 
Figure 2. Schematic diagram illustrating the following induction 
processes: (1) iPSCs can be differentiated into neural crest cells by FGF-2, 
followed by further differentiation on stiff matrix, with serum-free medium 
containing TGF-β1; differentiated VSMCs were then seeded onto 
biodegradable scaffold, followed by cyclic stretching to stimulate cell maturation 
and collagen synthesis; (2) iPSCs were differentiated into mesodermal cells 
using BMP4 combined with glycogen synthase kinase 3 inhibitor (CHIR99021 
or CP21), and then specified into two different fates, VSMCs and VECs, with 
either PDGF-BB+Activin-A or VEGF+Forskolin; (3) Parallel-plate flow chamber 
can maintain a consistent shear stress, which alters the cytoskeleton of iPSC 
and enhanced their differentiation capacities to VECs. Abbreviations: VSMCs, 
vascular smooth muscle cells; VECs, vascular endothelial cells; iPSCs, induced 
pluripotent stem cells; FGF-2, basic fibroblast growth factor; BMP4, bone 
morphogenetic orotein 4; TGF-β1, Transforming growth factor beta 1; PDGF-
BB, platelet-derived growth factor BB. 
 
 
Figure 3. Strategies to manufacture tissue engineered vascular graft 
(TEVG). A. Co-culture of VECs and hASCs on decellularized small 
intestinal submucosa: VECs from five different sources (HUVECs, hCECs, 
hPAECs, iCell-ECs hiPSC-ECs) were co-cultured with hASCs under controlled 
stimuli (growth factors, 3D hydrogel) in bio-incubator, resulting in spontaneous 
formation of vascular network via self-organization. Importantly, VECs were 
surrounded by hASCs as mural cells, forming small caliber lumens within the 
3D hydrogel. B. iPSC-derived VSMCs and VECs: Somatic cells can be 
isolated either from patients themselves or from other healthy individuals and 
then reprogrammed into hiPSCs. For homologous hiPSCs, gene-editing tool 
(CRISPR-Cas9) enables acquisition of hypoimmunogenic hiPSCs 
(B2m−/−/Ciita−/−/Cd47). Afterwards, hiPSC-VSMCs were seeded onto a scaffold 
with appropriate stiffness and then transferred into bio-incubator, where proper 











controlled precisely to generate preliminary TEVG. Thereafter, hiPSC-VECs 
coated the lumen of preliminary TEVG to create the final TEVG which are ready 
for vascular grafting. Abbreviations: VSMCs, vascular smooth muscle cells; 
VECs, vascular endothelial cells; hASCs, human adipose tissue-derived 
stromal cells; HUVECs, human umbilical vein endothelial cells; hCEC, human 
cardiac endothelial cell; hPAEC, human pulmonary artery endothelial cell; iCell-
ECs, iPSC derived endothelial cells from Cellular Dynamics International; EC, 
endothelial cells. 
 
Figure 4 Schematic representation of in vitro generation of hPSC-derived 
vascular organoids. Using this multi-step protocol as reported by Wimmer et 
al vascular organoids can be successfully created from hPSCs (human 
pluripotent stem cells) and maintained in culture dishes, which could be used 
for pathophysiological study, disease modelling, high-throughput drug 
screening, and in vivo transplantation, respectively.  
 
Figure 5. A diagrammatic representation of the original and vascularized 
whole-brain organoid protocols reported by a) Lancaster et al. 2014 as well 
as recently developed strategies of vascularization of human whole-brain 
organoids by b) Pham et al. 2018, c) Wörsdörfer et al. 2019, d) Cakir et al. 
2019, and e) Ham et al. 2020).  
 
Figure 6 Applications of in vitro vascular organotypic technology. A. 
Pluriopotent Stem Cell-derived vascular organoids may provide new insights 
into pivotal developmental events or signalling pathways during organogenesis. 
B. Patient-derived or gene-modified vascular organoids can be employed to 
study disease development, progression and oncogenesis. C. Patient-
compatible vascular organoids for application in regenerative medicine. D. 
Scalable, translatable vascular organoid-based platforms for high-throughput 
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